BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014;63:844-55. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 863] [Cited by in F6Publishing: 866] [Article Influence: 107.9] [Reference Citation Analysis]
Number Citing Articles
1 Hadjittofi C, Athanasopoulos PG, Koti RS, Konstantinidou SK, Davidson BR. Long-term survival with repeated resections of recurrent hepatocellular carcinoma in a non-cirrhotic liver: case report and brief review of the literature. Ann Transl Med 2016;4:112. [PMID: 27127765 DOI: 10.21037/atm.2016.03.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Gelli M, Sebagh M, Porcher R, Romanelli E, Vibert E, Sa Cunha A, Castaing D, Rosmorduc O, Samuel D, Adam R, Cherqui D. Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation. Ann Surg 2020;272:820-6. [PMID: 32833755 DOI: 10.1097/SLA.0000000000004259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Jin K, Wang K, Zhang H, Pan Y, Cao D, Wang M, Chen J, Wu D, Chen B, Xie X. Solitary Pulmonary Lesion in Patients with History of Malignancy: Primary Lung Cancer or Metastatic Cancer? Ann Surg Oncol 2018;25:1237-44. [PMID: 29417404 DOI: 10.1245/s10434-018-6360-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Sun B, Hu C, Yang Z, Zhang X, Zhao L, Xiong J, Ma J, Chen L, Qian H, Luo X, Shi L, Li J, Cheng X, Yin Z. Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells. Oncotarget 2017;8:32523-35. [PMID: 28430645 DOI: 10.18632/oncotarget.15808] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
5 Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, Brandi G, Pinna AD, Golfieri R. Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma? Radiology. 2016;279:432-442. [PMID: 26653683 DOI: 10.1148/radiol.2015150998] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 17.6] [Reference Citation Analysis]
6 Liang L, Li C, Wang MD, Wang H, Zhou YH, Zeng YY, Zhang WG, Chen TH, Wang NY, Li J, Zhang YM, Wang Y, Gu WM, Xing H, Diao YK, Lau WY, Zhang CW, Pawlik TM, Shen F, Huang DS, Yang T. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma. J Hematol Oncol 2021;14:165. [PMID: 34641921 DOI: 10.1186/s13045-021-01180-5] [Reference Citation Analysis]
7 Zhang Y, Wang Z, Yue ZD, Zhao HW, Wang L, Fan ZH, Wu YF, He FL, Liu FQ. Accurate ultrasonography-based portal pressure assessment in patients with hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(8): 931-941 [PMID: 32879669 DOI: 10.4251/wjgo.v12.i8.931] [Reference Citation Analysis]
8 Yin X, Xiao Y, Han L, Zhang B, Wang T, Su Z, Zhang N. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma. AAPS PharmSciTech 2018;19:2133-43. [PMID: 29714002 DOI: 10.1208/s12249-018-1005-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
9 Yu J, Li X, Tao Q, Yu XL, Cheng ZG, Han ZY, Guo M, Liang P. Hypermethylation of ZNF545 is associated with poor prognosis in patients with early-stage hepatocellular carcinoma after thermal ablation. Gut 2015;64:1836-7. [PMID: 26289056 DOI: 10.1136/gutjnl-2015-310258] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
10 Wang ZF, Hu R, Pang JM, Zhang GZ, Yan W, Li ZN. Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma. Oncol Lett. 2018;16:1593-1601. [PMID: 30008842 DOI: 10.3892/ol.2018.8825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yu Z, Zhang Y, Shao S, Liu Q, Li Y, Du X, Zhang K, Zhang M, Yuan H, Yuan Q, Liu T, Gao Y, Wang Y, Hong W, Han T. Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma. Front Oncol 2021;11:755814. [PMID: 34660326 DOI: 10.3389/fonc.2021.755814] [Reference Citation Analysis]
12 Zhang L, Tao H, Li J, Zhang E, Liang H, Zhang B. Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma. Aging (Albany NY) 2021;13:15990-6008. [PMID: 34049287 DOI: 10.18632/aging.203056] [Reference Citation Analysis]
13 Zhao B, Lu Y, Cao X, Zhu W, Kong L, Ji H, Zhang F, Lin X, Guan Q, Ou K, Zhang X, Chen Q. MiRNA-124 inhibits the proliferation, migration and invasion of cancer cell in hepatocellular carcinoma by downregulating lncRNA-UCA1. Onco Targets Ther 2019;12:4509-16. [PMID: 31354286 DOI: 10.2147/OTT.S205169] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
14 Huang F, Chen J, Lan R, Wang Z, Chen R, Lin J, Fu L. Hypoxia induced δ-Catenin to enhance mice hepatocellular carcinoma progression via Wnt signaling. Exp Cell Res 2019;374:94-103. [PMID: 30458179 DOI: 10.1016/j.yexcr.2018.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mao J, Yang H, Cui T, Pan P, Kabir N, Chen D, Ma J, Chen X, Chen Y, Yang Y. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. Eur J Pharmacol 2018;832:39-49. [PMID: 29782854 DOI: 10.1016/j.ejphar.2018.05.027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
16 Xia C, Zhang XY, Liu W, Ju M, Ju Y, Bu YZ, Wang W, Shao H. LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial-mesenchymal transition. J Cell Biochem. 2018;. [PMID: 30506763 DOI: 10.1002/jcb.28074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
17 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
18 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
19 Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World J Gastroenterol 2017; 23(18): 3195-3204 [PMID: 28566879 DOI: 10.3748/wjg.v23.i18.3195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Akamatsu N, Sugawara Y, Kokudo N. Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma. World J Hepatol 2014; 6(9): 626-631 [PMID: 25276278 DOI: 10.4254/wjh.v6.i9.626] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
21 Hu CL, Du QC, Wang ZX, Pang MQ, Wang YY, Li YY, Zhou Y, Wang HJ, Fan HN. Relationship between platelet-based models and the prognosis of patients with malignant hepatic tumors. Oncol Lett 2020;19:2384-96. [PMID: 32194738 DOI: 10.3892/ol.2020.11317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Lee SJ, Won HJ, Kim KW, Shin YM, Kim PN. Value of contrast-enhanced sonography of small hepatocellular carcinoma with sonazoid prior to radiofrequency ablation. J Clin Ultrasound 2017;45:383-90. [PMID: 28271531 DOI: 10.1002/jcu.22469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Yin LC, Xiao G, Zhou R, Huang XP, Li NL, Tan CL, Xie FJ, Weng J, Liu LX. MicroRNA-361-5p Inhibits Tumorigenesis and the EMT of HCC by Targeting Twist1. Biomed Res Int 2020;2020:8891876. [PMID: 33381597 DOI: 10.1155/2020/8891876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Shi C, Cai Y, Li Y, Li Y, Hu N, Ma S, Hu S, Zhu P, Wang W, Zhou H. Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways. Redox Biol 2018;14:59-71. [PMID: 28869833 DOI: 10.1016/j.redox.2017.08.013] [Cited by in Crossref: 144] [Cited by in F6Publishing: 143] [Article Influence: 28.8] [Reference Citation Analysis]
25 Hester CA, Yopp AC. Surgical Therapies in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 145-67. [DOI: 10.1007/978-3-030-21540-8_8] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Li M, Ren ZG, Cui JF. Advances in understanding of mechanism of anti-hepatocellular carcinoma effects of curcumin. Shijie Huaren Xiaohua Zazhi 2019; 27(17): 1043-1049 [DOI: 10.11569/wcjd.v27.i17.1043] [Reference Citation Analysis]
27 Wang J, Lian Y, Gu Y, Wang H, Gu L, Huang Y, Zhou L, Huang Y. Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells. Oncotarget 2017;8:105047-60. [PMID: 29285232 DOI: 10.18632/oncotarget.22086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
28 Ge S, Xu Y, Wang H, Sun Y, Tian X, Cao Z, Lin X, Xu J, Wang Q. Downregulation of esophageal cancer-related gene 4 promotes proliferation and migration of hepatocellular carcinoma. Oncol Lett 2017;14:3689-96. [PMID: 28927132 DOI: 10.3892/ol.2017.6616] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wan T, Zheng J, Yao R, Yang S, Zheng W, Zhou P. LncRNA DDX11-AS1 accelerates hepatocellular carcinoma progression via the miR-195-5p/MACC1 pathway. Ann Hepatol 2021;20:100258. [PMID: 32961346 DOI: 10.1016/j.aohep.2020.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Roskilly A, Rowe IA. Surveillance for hepatocellular cancer. Clin Med (Lond). 2018;18:s66-s69. [PMID: 29700096 DOI: 10.7861/clinmedicine.18-2-s66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jiang S, Wang Q, Feng M, Li J, Guan Z, An D, Dong M, Peng Y, Kuerban K, Ye L. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. Appl Microbiol Biotechnol. 2017;101:1535-1546. [PMID: 27807662 DOI: 10.1007/s00253-016-7930-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
32 Wei Y, Pei W, Qin Y, Su D, Liao H. Preoperative MR imaging for predicting early recurrence of solitary hepatocellular carcinoma without microvascular invasion. Eur J Radiol 2021;138:109663. [PMID: 33773401 DOI: 10.1016/j.ejrad.2021.109663] [Reference Citation Analysis]
33 Chen H, Yang X, Yu Z, Cheng Z, Yuan H, Zhao Z, Wu G, Xie N, Yuan X, Sun Q, Zhang W. Synthesis and biological evaluation of α-santonin derivatives as anti-hepatoma agents. Eur J Med Chem 2018;149:90-7. [PMID: 29499490 DOI: 10.1016/j.ejmech.2018.02.073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
34 Li L, Li B, Zhang M. Postoperative adjuvant transarterial chemoembolization improves the prognosis of hepatocellular carcinoma patients with microvascular invasion: a systematic review and meta-analysis. Acta Radiol 2020;61:723-31. [PMID: 31594382 DOI: 10.1177/0284185119878357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Song S, Shi Y, Wu W, Wu H, Chang L, Peng P, Zhang L, Fan J, Gu J, Ruan Y. Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus. Gut 2021;70:2159-71. [PMID: 33303565 DOI: 10.1136/gutjnl-2020-321386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
36 Zhou C, Wang P, Tu M, Huang Y, Xiong F, Wu Y. Long Non-Coding RNA PART1 Promotes Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cells via miR-149-5p/MAP2K1 Axis. Cancer Manag Res 2020;12:3771-82. [PMID: 32547213 DOI: 10.2147/CMAR.S246311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
37 Chen L, Guan H, Gu C, Cao Y, Shao J, Wang F. miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL. Tumor Biol 2016;37:2497-507. [DOI: 10.1007/s13277-015-4071-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
38 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053 [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
39 Huang M, Liao B, Xu P, Cai H, Huang K, Dong Z, Xu L, Peng Z, Luo Y, Zheng K, Peng B, Li ZP, Feng ST. Prediction of Microvascular Invasion in Hepatocellular Carcinoma: Preoperative Gd-EOB-DTPA-Dynamic Enhanced MRI and Histopathological Correlation. Contrast Media Mol Imaging. 2018;2018:9674565. [PMID: 29606926 DOI: 10.1155/2018/9674565] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
40 Chiyonobu N, Shimada S, Akiyama Y, Mogushi K, Itoh M, Akahoshi K, Matsumura S, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Suganami T, Yamaoka S, Ogawa Y, Tanabe M, Tanaka S. Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors. Am J Pathol 2018;188:1213-24. [PMID: 29454748 DOI: 10.1016/j.ajpath.2018.01.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
41 Hendriquez R, Keihanian T, Goyal J, Abraham RR, Mishra R, Girotra M. Radiofrequency ablation in the management of primary hepatic and biliary tumors. World J Gastrointest Oncol 2022; 14(1): 203-215 [DOI: 10.4251/wjgo.v14.i1.203] [Reference Citation Analysis]
42 Zhang G, Zhang G. Upregulation of FoxP4 in HCC promotes migration and invasion through regulation of EMT. Oncol Lett 2019;17:3944-51. [PMID: 30930991 DOI: 10.3892/ol.2019.10049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
43 Zeng T, Wang D, Chen J, Tian Y, Cai X, Peng H, Zhu L, Huang A, Tang H. LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells. PLoS One 2017;12:e0177843. [PMID: 28542387 DOI: 10.1371/journal.pone.0177843] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
44 Li X, An M, Gao Z. In Hepatocellular Carcinoma, miRNA-296-3p Targets MSL2 and Suppresses Cell Proliferation and Invasion. J Oncol 2021;2021:7430468. [PMID: 34899909 DOI: 10.1155/2021/7430468] [Reference Citation Analysis]
45 Xue S, Lu F, Sun C, Zhao J, Zhen H, Li X. LncRNA ZEB1-AS1 regulates hepatocellular carcinoma progression by targeting miR-23c. World J Surg Oncol 2021;19:121. [PMID: 33865414 DOI: 10.1186/s12957-021-02176-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Yao M, Pan LH, Yao DF. Glypican-3 as a specific biomarker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14:122-123. [PMID: 25865682 DOI: 10.1016/s1499-3872(15)60350-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
47 Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol 2018;31:670-9. [PMID: 30386116 DOI: 10.20524/aog.2018.0306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
48 Montasser A, Beaufrère A, Cauchy F, Bouattour M, Soubrane O, Albuquerque M, Paradis V. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology 2021;79:36-46. [PMID: 33326644 DOI: 10.1111/his.14317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Li X, Liu S, Li H, Guo L, Zhang B, Lin Z, Zhang J, Ye Q. Proper hepatic pedicle clamping during hepatectomy is associated with improved postoperative long-term prognosis in patients with AJCC stage IIIB hepatocellular carcinoma. Oncotarget 2016;7:24623-32. [PMID: 27027437 DOI: 10.18632/oncotarget.8331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
50 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424 [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
51 Chen R, Gao Z, Wu X, Campbell JL, Zhang P, Chen B. Hepatocellular carcinoma presenting as thoracic spinal canal metastasis with no clinical primary foci: A report of a rare case and review of the literature. Oncol Lett 2015;10:2333-6. [PMID: 26622846 DOI: 10.3892/ol.2015.3569] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
52 Zhu X, Wu Y, Miao X, Li C, Yin H, Yang S, Lu X, Liu Y, Chen Y, Shen R, Chen X, He S. High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma. Tumour Biol 2016;37:14615-28. [PMID: 27619678 DOI: 10.1007/s13277-016-5316-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
53 Ferrer-Fàbrega J, Forner A, Liccioni A, Miquel R, Molina V, Navasa M, Fondevila C, García-Valdecasas JC, Bruix J, Fuster J. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 2016;63:839-49. [PMID: 26567038 DOI: 10.1002/hep.28339] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 12.5] [Reference Citation Analysis]
54 Li M, Yin Z, Hu B, Guo N, Zhang L, Zhang L, Zhu J, Chen W, Yin M, Chen J, Ehman RL, Wang J. MR Elastography-Based Shear Strain Mapping for Assessment of Microvascular Invasion in Hepatocellular Carcinoma. Eur Radiol 2022. [PMID: 35147777 DOI: 10.1007/s00330-022-08578-w] [Reference Citation Analysis]
55 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
56 Hernaez R, El-Serag HB. How we approach it: treatment options for hepatocellular carcinoma. Am J Gastroenterol 2018;113:791-4. [PMID: 29713029 DOI: 10.1038/s41395-018-0008-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
57 Wang H, Kohashi K, Yoshizumi T, Okumura Y, Tanaka Y, Shimokawa M, Iwasaki T, Aishima S, Maehara Y, Oda Y. Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol 2017;64:69-75. [PMID: 28411180 DOI: 10.1016/j.humpath.2017.03.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
58 Hu S, Tu J, Jia Z, Huang Y, Jiang G. Transarterial embolization/chemoembolization therapy for hepatocellular carcinoma fed by adrenal artery: Preliminary results. Medicine 2016;95:e5762. [DOI: 10.1097/md.0000000000005762] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
59 Zhu X, Luo W, Bei C, Kong J, Zhang S, Fu Y, Li D, Tan S. Correlations between chromobox homolog 8 and key factors of epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Cell Int 2019;19:340. [PMID: 31889893 DOI: 10.1186/s12935-019-1063-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
60 Jin GZ, Dong W, Dong H, Yu H, Chen J, Yu WL, Li AJ, Cong WM, Wu MC. The diagnostic and prognostic value of MRP8/MRP14 in intrahepatic cholangiocarcinoma. Oncotarget 2015;6:39357-64. [PMID: 26472105 DOI: 10.18632/oncotarget.5329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
61 Ding L, Xiao L, Lin X, Xiong C, Lin L, Chen S. Intravoxel Incoherent Motion (IVIM) Diffusion-Weighted Imaging (DWI) in Patients with Liver Dysfunction of Chronic Viral Hepatitis: Segmental Heterogeneity and Relationship with Child-Turcotte-Pugh Class at 3 Tesla. Gastroenterol Res Pract. 2018;2018:2983725. [PMID: 30647733 DOI: 10.1155/2018/2983725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Mazzoccoli G, Miele L, Marrone G, Mazza T, Vinciguerra M, Grieco A. A Role for the Biological Clock in Liver Cancer. Cancers (Basel) 2019;11:E1778. [PMID: 31718031 DOI: 10.3390/cancers11111778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
63 Kinoshita A, Onoda H, Ueda K, Imai N, Iwaku A, Tanaka K, Fushiya N, Koike K, Nishino H, Tajiri H. Clinical characteristics and survival outcomes of super-elderly hepatocellular carcinoma patients not indicated for surgical resection. Hepatol Res 2016;46:E5-E14. [PMID: 25753133 DOI: 10.1111/hepr.12514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
64 Li Z, Hu Y, Zeng Q, Wang H, Yan J, Li H, Yu Z. Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p. Cancer Cell Int 2019;19:211. [PMID: 31413665 DOI: 10.1186/s12935-019-0926-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
65 Deng L, Yang C, Li LQ, Zhong JH. Hepatic Resection Improves Long-Term Survival of Patients with Large and/or Multinodular Hepatocellular Carcinoma. J Gastrointest Surg 2015;19:2288-9. [PMID: 26464016 DOI: 10.1007/s11605-015-2965-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 Shen D, Zhao HY, Gu AD, Wu YW, Weng YH, Li SJ, Song JY, Gu XF, Qiu J, Zhao W. miRNA-10a-5p inhibits cell metastasis in hepatocellular carcinoma via targeting SKA1. Kaohsiung J Med Sci 2021;37:784-94. [PMID: 34002462 DOI: 10.1002/kjm2.12392] [Reference Citation Analysis]
67 Jiang X, Shen X. Knockdown of miR-299-5p inhibits the progression of hepatocellular carcinoma by targeting SIAH1. Bull Cancer 2018;105:873-83. [PMID: 30266288 DOI: 10.1016/j.bulcan.2018.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
68 Tong Y, Wang M, Huang H, Zhang J, Huang Y, Chen Y, Pan H. Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line. Exp Ther Med 2019;18:3793-800. [PMID: 31611933 DOI: 10.3892/etm.2019.8027] [Reference Citation Analysis]
69 Shao D, Li J, Zheng X, Pan Y, Wang Z, Zhang M, Chen Q, Dong W, Chen L. Janus “nano-bullets” for magnetic targeting liver cancer chemotherapy. Biomaterials 2016;100:118-33. [DOI: 10.1016/j.biomaterials.2016.05.030] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 14.5] [Reference Citation Analysis]
70 Liu X, Yu L, Han C, Lu S, Zhu G, Su H, Qin W, Liao X, Peng T. Polymorphisms of HLA-DQB1 predict survival of hepatitis B virus-related hepatocellular carcinoma patients receiving hepatic resection. Clin Res Hepatol Gastroenterol 2016;40:739-47. [PMID: 27288300 DOI: 10.1016/j.clinre.2016.04.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
71 An J, Zhang Z, Liu Z, Wang R, Hui D, Jin Y. Overexpression of Cullin7 is associated with hepatocellular carcinoma progression and pathogenesis. BMC Cancer 2017;17:828. [PMID: 29207970 DOI: 10.1186/s12885-017-3839-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
72 Zhao L, Lou G, Li A, Liu Y. lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR‑375 sponging. Mol Med Rep 2020;22:1449-57. [PMID: 32626943 DOI: 10.3892/mmr.2020.11196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
73 Tao R, Wang ZF, Qiu W, He YF, Yan WQ, Sun WY, Li HJ. Role of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium cantharidinate. Exp Ther Med 2017;13:2812-8. [PMID: 28588665 DOI: 10.3892/etm.2017.4294] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
74 He L, Fan X, Li Y, Chen M, Cui B, Chen G, Dai Y, Zhou D, Hu X, Lin H. Overexpression of zinc finger protein 384 (ZNF 384), a poor prognostic predictor, promotes cell growth by upregulating the expression of Cyclin D1 in Hepatocellular carcinoma. Cell Death Dis 2019;10:444. [PMID: 31168049 DOI: 10.1038/s41419-019-1681-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Yu J, Yu XL, Han ZY, Cheng ZG, Liu FY, Zhai HY, Mu MJ, Liu YM, Liang P. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut 2017;66:1172-3. [PMID: 27884919 DOI: 10.1136/gutjnl-2016-312629] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 15.2] [Reference Citation Analysis]
76 Yan Y, Lu Y, Mao K, Zhang M, Liu H, Zhou Q, Lin J, Zhang J, Wang J, Xiao Z. Identification and validation of a prognostic four-genes signature for hepatocellular carcinoma: integrated ceRNA network analysis. Hepatol Int 2019;13:618-30. [PMID: 31321712 DOI: 10.1007/s12072-019-09962-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
77 Diniz PHC, Silva SDC, Vidigal PVT, Xavier MAP, Lima CX, Faria LC, Ferrari TCA. Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma. J Oncol 2020;2020:4609360. [PMID: 33178273 DOI: 10.1155/2020/4609360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
78 Pang Q, Bi JB, Wang ZX, Xu XS, Qu K, Miao RC, Chen W, Zhou YY, Liu C. Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma. Onco Targets Ther 2016;9:2099-109. [PMID: 27110127 DOI: 10.2147/OTT.S101465] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
79 Dong H, Zhang Y, Xu Y, Ma R, Liu L, Luo C, Jiang W. Downregulation of long non-coding RNA MEG3 promotes proliferation, migration, and invasion of human hepatocellular carcinoma cells by upregulating TGF-β1. Acta Biochim Biophys Sin (Shanghai) 2019;51:645-52. [PMID: 31089680 DOI: 10.1093/abbs/gmz046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
80 Chen D, Liu S, Chen S, Wang Z, Wu Z, Ma K, Fan J, Peng Z. Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation. Int J Clin Oncol 2016;21:1111-9. [PMID: 27368337 DOI: 10.1007/s10147-016-1001-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
81 Sun DW, Zhang YY, Sun XD, Chen YG, Qiu W, Ji M, Lv GY. Prognostic value of cytokeratin 19 in hepatocellular carcinoma: A meta-analysis. Clin Chim Acta 2015;448:161-9. [PMID: 26164382 DOI: 10.1016/j.cca.2015.06.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
82 Yamada N, Matsushima-nishiwaki R, Kozawa O. Quercetin suppresses the migration of hepatocellular carcinoma cells stimulated by hepatocyte growth factor or transforming growth factor-α: Attenuation of AKT signaling pathway. Archives of Biochemistry and Biophysics 2020;682:108296. [DOI: 10.1016/j.abb.2020.108296] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
83 Chen W, Quan Y, Fan S, Wang H, Liang J, Huang L, Chen L, Liu Q, He P, Ye Y. Exosome-transmitted circular RNA hsa_circ_0051443 suppresses hepatocellular carcinoma progression. Cancer Lett 2020;475:119-28. [PMID: 32014458 DOI: 10.1016/j.canlet.2020.01.022] [Cited by in Crossref: 54] [Cited by in F6Publishing: 65] [Article Influence: 27.0] [Reference Citation Analysis]
84 Zhong J, Dong X, Xiu P, Wang F, Liu J, Wei H, Xu Z, Liu F, Li T, Li J. Blocking autophagy enhances meloxicam lethality to hepatocellular carcinoma by promotion of endoplasmic reticulum stress. Cell Prolif 2015;48:691-704. [PMID: 26481188 DOI: 10.1111/cpr.12221] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
85 Wang D, Wu Q, Guo R, Lu C, Niu M, Rao W. Magnetic liquid metal loaded nano-in-micro spheres as fully flexible theranostic agents for SMART embolization. Nanoscale 2021;13:8817-36. [PMID: 33960346 DOI: 10.1039/d1nr01268a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Nahon P, Sutton A, Ziol M, Zucman-Rossi J, Trinchet J-C, Ganne-Carrié N. Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease. Hepatic Oncol. 2015;2:63-78. [PMID: 30190987 DOI: 10.2217/hep.14.26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
87 Govaere O, Roskams T. Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels. Clin Liver Dis. 2015;19:261-276. [PMID: 25921662 DOI: 10.1016/j.cld.2015.01.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
88 Xie ZB, Wang XB, Peng YC, Zhu SL, Ma L, Xiang BD, Gong WF, Chen J, You XM, Jiang JH, Li LQ, Zhong JH. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45:190-200. [PMID: 25388603 DOI: 10.1111/hepr.12450] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
89 Sasaki R, Kanda T, Kato N, Yokosuka O, Moriyama M. Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. World J Hepatol 2018; 10(12): 898-906 [PMID: 30631394 DOI: 10.4254/wjh.v10.i12.898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
90 Li B, Xu T, Liu C, Meng G, Sun Y, Qian L, Wang S, Wei J, Yu D, Ding Y. Liver-enriched Genes are Associated with the Prognosis of Patients with Hepatocellular Carcinoma. Sci Rep 2018;8:11197. [PMID: 30046116 DOI: 10.1038/s41598-018-29237-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
91 Govaere O, Petz M, Wouters J, Vandewynckel YP, Scott EJ, Topal B, Nevens F, Verslype C, Anstee QM, Van Vlierberghe H, Mikulits W, Roskams T. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene 2017;36:6605-16. [PMID: 28783171 DOI: 10.1038/onc.2017.260] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
92 Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. J Exp Clin Cancer Res 2019;38:232. [PMID: 31151472 DOI: 10.1186/s13046-019-1216-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
93 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
94 Long G, Fang T, Su W, Mi X, Zhou L. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. Scand J Gastroenterol 2020;55:1441-6. [PMID: 33119422 DOI: 10.1080/00365521.2020.1839127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Wei J, Liu Y, Zhao C. Integrated Analysis of FAM57A Expression and Its Potential Roles in Hepatocellular Carcinoma. Front Oncol 2021;11:719973. [PMID: 34790567 DOI: 10.3389/fonc.2021.719973] [Reference Citation Analysis]
96 Naidoo S, Daniels A, Habib S, Singh M. Poly-L-Lysine-Lactobionic Acid-Capped Selenium Nanoparticles for Liver-Targeted Gene Delivery. Int J Mol Sci 2022;23:1492. [PMID: 35163414 DOI: 10.3390/ijms23031492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Wu W, Yang JL, Wang YL, Wang H, Yao M, Wang L, Gu JJ, Cai Y, Shi Y, Yao DF. Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF-κB gene transcription. World J Hepatol 2016; 8(23): 985-993 [PMID: 27621764 DOI: 10.4254/wjh.v8.i23.985] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
98 Wang H, Li Y, Lu J, Qiu M, Cheng D, Zhang X, Yuan W. Shengbai decoction enhances the anti-tumor efficacy of cyclophosphamide on hepatoma 22-bearing mice. Biomed Pharmacother 2021;140:111775. [PMID: 34062413 DOI: 10.1016/j.biopha.2021.111775] [Reference Citation Analysis]
99 Chen Y, Chen HN, Wang K, Zhang L, Huang Z, Liu J, Zhang Z, Luo M, Lei Y, Peng Y, Zhou ZG, Wei Y, Huang C. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol 2019;70:66-77. [PMID: 30287340 DOI: 10.1016/j.jhep.2018.09.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
100 Hou C, Guo D, Yu X, Wang S, Liu T. TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. Biomed Pharmacother 2020;126:109862. [PMID: 32120157 DOI: 10.1016/j.biopha.2020.109862] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
101 Yu L, Wang Z, Mo Z, Zou B, Yang Y, Sun R, Ma W, Yu M, Zhang S, Yu Z. Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy. Acta Pharm Sin B 2021;11:2004-15. [PMID: 34386334 DOI: 10.1016/j.apsb.2021.02.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 31.0] [Reference Citation Analysis]
102 Pan L, Xiao H, Liao R, Chen Q, Peng C, Zhang Y, Mu T, Wu Z. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma. Biomed Pharmacother 2018;106:68-76. [PMID: 29957468 DOI: 10.1016/j.biopha.2018.06.040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
103 Kim MY, Lee H, Ji SY, Kim SY, Hwangbo H, Park SH, Kim GY, Park C, Leem SH, Hong SH, Choi YH. Induction of Apoptosis by Isoalantolactone in Human Hepatocellular Carcinoma Hep3B Cells through Activation of the ROS-Dependent JNK Signaling Pathway. Pharmaceutics 2021;13:1627. [PMID: 34683920 DOI: 10.3390/pharmaceutics13101627] [Reference Citation Analysis]
104 Luo Q, Wang C, Jin G, Gu D, Wang N, Song J, Jin H, Hu F, Zhang Y, Ge T, Huo X, Chu W, Shu H, Fang J, Yao M, Gu J, Cong W, Qin W. LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway. Carcinogenesis 2015;36:1201-12. [PMID: 26249360 DOI: 10.1093/carcin/bgv108] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
105 Sun WY, Hu SS, Wu JJ, Huang Q, Ma Y, Wang QT, Chen JY, Wei W. Down-regulation of β-arrestin2 promotes tumour invasion and indicates poor prognosis of hepatocellular carcinoma. Sci Rep 2016;6:35609. [PMID: 27759077 DOI: 10.1038/srep35609] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
106 Liu ZC, Ning F, Wang HF, Chen DY, Cai YN, Sheng HY, Lash GE, Liu L, Du J. Epidermal growth factor and tumor necrosis factor α cooperatively promote the motility of hepatocellular carcinoma cell lines via synergistic induction of fibronectin by NF-κB/p65. Biochim Biophys Acta Gen Subj 2017;1861:2568-82. [PMID: 28844984 DOI: 10.1016/j.bbagen.2017.08.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
107 Pan L, Yao M, Zheng W, Gu J, Yang X, Qiu L, Cai Y, Wu W, Yao D. Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma. Tumour Biol. 2016;37:5561-5568. [PMID: 26577850 DOI: 10.1007/s13277-015-4413-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
108 Wang T, Ma S, Qi X, Tang X, Cui D, Wang Z, Chi J, Li P, Zhai B. Long noncoding RNA ZNFX1-AS1 suppresses growth of hepatocellular carcinoma cells by regulating the methylation of miR-9. Onco Targets Ther 2016;9:5005-14. [PMID: 27574442 DOI: 10.2147/OTT.S103329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
109 Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu AL, Brunner TB. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol 2017;12:116. [PMID: 28701219 DOI: 10.1186/s13014-017-0851-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
110 Ma XL, Qu XD, Yang WJ, Wang BL, Shen MN, Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, Gong ZJ, Zhang X, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. Clin Chim Acta 2020;511:67-74. [PMID: 32979338 DOI: 10.1016/j.cca.2020.09.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Liu P, Chen L, Zhang H. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy. J Immunol Res 2018;2018:1206737. [PMID: 30255103 DOI: 10.1155/2018/1206737] [Cited by in Crossref: 34] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
112 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
113 Zhang X, Huang G, Ye J, Xu M, Cong L, He X, Huang T, Kuang M, Xie X. 3-D Contrast-Enhanced Ultrasound Fusion Imaging: A New Technique to Evaluate the Ablative Margin of Radiofrequency Ablation for Hepatocellular Carcinoma. Ultrasound Med Biol 2019;45:1933-43. [PMID: 31109841 DOI: 10.1016/j.ultrasmedbio.2019.03.019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Kuchuk O, Tuccitto A, Citterio D, Huber V, Camisaschi C, Milione M, Vergani B, Villa A, Alison MR, Carradori S, Supuran CT, Rivoltini L, Castelli C, Mazzaferro V. pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. Oncoimmunology 2018;7:e1445452. [PMID: 29900055 DOI: 10.1080/2162402X.2018.1445452] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
115 Shi Z, Xing H, Qi C, Fang M, Fu J, Zhang X. Chinese tree shrews as a primate experimental animal eligible for the study of alcoholic liver disease: characterization and confirmation by MRI. Exp Anim 2020;69:110-8. [PMID: 31554748 DOI: 10.1538/expanim.19-0073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Pang J, Li Z, Wang G, Li N, Gao Y, Wang S. miR-214-5p targets KLF5 and suppresses proliferation of human hepatocellular carcinoma cells. J Cell Biochem 2018. [PMID: 30206974 DOI: 10.1002/jcb.27498] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
117 Liu Z, Li W, Pang Y, Zhou Z, Liu S, Cheng K, Qin Q, Jia Y, Liu S. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma. EBioMedicine 2018;38:57-68. [PMID: 30391496 DOI: 10.1016/j.ebiom.2018.10.067] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
118 Gkika E, Tanadini-lang S, Kirste S, Holzner PA, Neeff HP, Rischke HC, Reese T, Lohaus F, Duma MN, Dieckmann K, Semrau R, Stockinger M, Imhoff D, Kremers N, Häfner MF, Andratschke N, Nestle U, Grosu AL, Guckenberger M, Brunner TB. Interobserver variability in target volume delineation of hepatocellular carcinoma: An analysis of the working group “Stereotactic Radiotherapy” of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol 2017;193:823-30. [DOI: 10.1007/s00066-017-1177-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
119 Mo Z, Wang Y, Cao Z, Li P, Zhang S. An Integrative Analysis Reveals the Underlying Association Between CTNNB1 Mutation and Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2020;10:853. [PMID: 32596147 DOI: 10.3389/fonc.2020.00853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Zhao YF, Xiong X, Chen K, Tang W, Yang X, Shi ZR. Evaluation of the Therapeutic Effect of Adjuvant Transcatheter Arterial Chemoembolization Based on Ki67 After Hepatocellular Carcinoma Surgery. Front Oncol 2021;11:605234. [PMID: 33718156 DOI: 10.3389/fonc.2021.605234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Zhang J, Wang T, Mu S, Olerile LD, Yu X, Zhang N. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy. Nanomedicine 2017;12:911-25. [DOI: 10.2217/nnm-2016-0402] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
122 He J, Li G, Liu X, Ma L, Zhang P, Zhang J, Zheng S, Wang J, Liu J. Diagnostic and Prognostic Values of MANF Expression in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:1936385. [PMID: 32382531 DOI: 10.1155/2020/1936385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Kolly P, Reeves H, Sangro B, Knöpfli M, Candinas D, Dufour J. Assessment of the Hong Kong Liver Cancer Staging System in Europe. Liver Int 2016;36:911-7. [DOI: 10.1111/liv.13045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
124 Zhang HH, Zhang Y, Cheng YN, Gong FL, Cao ZQ, Yu LG, Guo XL. Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo. Mol Carcinog 2018;57:44-56. [PMID: 28833603 DOI: 10.1002/mc.22718] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
125 Li X, Chen ZH, Xing YF, Wang TT, Wu DH, Wen JY, Chen J, Lin Q, Dong M, Wei L. Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol. 2015;36:2263-2269. [PMID: 25409616 DOI: 10.1007/s13277-014-2833-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 6.4] [Reference Citation Analysis]
126 Liu Z, Ding F, Shen X. Total flavonoids of Radix Tetrastigma suppress inflammation-related hepatocellular carcinoma cell metastasis. Mol Genet Genomics 2021;296:571-9. [PMID: 33576897 DOI: 10.1007/s00438-020-01759-6] [Reference Citation Analysis]
127 Zheng J, Shen S, Jiang L, Yan L, Yang J, Li B, Wen T, Wang W, Xu M. Outcomes of anterior approach major hepatectomy with diaphragmatic resection for single huge right lobe HCC with diaphragmatic invasion. Medicine (Baltimore) 2018;97:e12194. [PMID: 30200125 DOI: 10.1097/MD.0000000000012194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
128 Alim A, Erdogan Y, Dayangac M, Yuzer Y, Tokat Y, Oezcelik A. Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria. Cancer Control 2021;28:10732748211011960. [PMID: 33926242 DOI: 10.1177/10732748211011960] [Reference Citation Analysis]
129 Zhang Y, Jia QA, Kadel D, Zhang XF, Zhang QB. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC). Med Sci Monit 2018;24:2735-43. [PMID: 29720580 DOI: 10.12659/MSM.907514] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
130 Tang SJ, Yang JB. LncRNA SNHG14 aggravates invasion and migration as ceRNA via regulating miR-656-3p/SIRT5 pathway in hepatocellular carcinoma. Mol Cell Biochem 2020;473:143-53. [PMID: 32607966 DOI: 10.1007/s11010-020-03815-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Tsai MY, Yen YH, Huang PY, Sou FM, Lin CC, Cho WR, Wang HM, Chen DW, Chang KC, Wu CK, Hu TH, Tsai MC. The Pre- and Postoperative FIB-4 Indexes Are Good Predictors to the Outcomes of HBV-Related HCC Patients after Resection. Gastroenterol Res Pract 2019;2019:8945798. [PMID: 31885547 DOI: 10.1155/2019/8945798] [Reference Citation Analysis]
132 Long J, Zhang L, Wan X, Lin J, Bai Y, Xu W, Xiong J, Zhao H. A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma. J Cell Mol Med. 2018;22:5928-5938. [PMID: 30247807 DOI: 10.1111/jcmm.13863] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
133 Lapitz A, Arbelaiz A, Olaizola P, Aranburu A, Bujanda L, Perugorria MJ, Banales JM. Extracellular Vesicles in Hepatobiliary Malignancies. Front Immunol 2018;9:2270. [PMID: 30369925 DOI: 10.3389/fimmu.2018.02270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
134 Bruix J, Gores G, Mazzaferro V. Authors' response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al. Gut 2015;64:522. [PMID: 25311033 DOI: 10.1136/gutjnl-2014-308381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, Cai J, Poon RT, Han K-H, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre Marie-Aude, Meinhardt G, Llovet JM, investigators S. Articles Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16: :1344-1354. [PMID: 26361969 DOI: 10.1016/s1470-2045(15)00198-9] [Cited by in Crossref: 436] [Cited by in F6Publishing: 222] [Article Influence: 62.3] [Reference Citation Analysis]
136 Marin JJG, Romero MR, Herraez E, Asensio M, Ortiz-Rivero S, Sanchez-Martin A, Fabris L, Briz O. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Semin Liver Dis 2021. [PMID: 34544160 DOI: 10.1055/s-0041-1735631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Xing H, Zhang WG, Cescon M, Liang L, Li C, Wang MD, Wu H, Lau WY, Zhou YH, Gu WM, Wang H, Chen TH, Zeng YY, Schwartz M, Pawlik TM, Serenari M, Shen F, Wu MC, Yang T. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford) 2020;22:677-89. [PMID: 31607637 DOI: 10.1016/j.hpb.2019.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
138 Chen J, Li X, Ma D, Liu T, Tian P, Wu C. Ceramide synthase-4 orchestrates the cell proliferation and tumor growth of liver cancer in vitro and in vivo through the nuclear factor-κB signaling pathway. Oncol Lett 2017;14:1477-83. [PMID: 28789368 DOI: 10.3892/ol.2017.6365] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
139 Wang J, Su S, Zhang S, Zhai S, Sheng R, Wu W, Guo R. Structure-activity relationship and synthetic methodologies of α-santonin derivatives with diverse bioactivities: A mini-review. European Journal of Medicinal Chemistry 2019;175:215-33. [DOI: 10.1016/j.ejmech.2019.04.066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
140 Chu PS, Nakamoto N, Taniki N, Ojiro K, Amiya T, Makita Y, Murata H, Yamaguchi A, Shiba S, Miyake R, Katayama T, Ugamura A, Ikura A, Takeda K, Ebinuma H, Saito H, Kanai T. On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. PLoS One. 2017;12:e0179096. [PMID: 28617830 DOI: 10.1371/journal.pone.0179096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
141 Akbari S, Kunter I, Azbazdar Y, Ozhan G, Atabey N, Firtina Karagonlar Z, Erdal E. LGR5/R-Spo1/Wnt3a axis promotes stemness and aggressive phenotype in hepatoblast-like hepatocellular carcinoma cell lines. Cell Signal 2021;82:109972. [PMID: 33684507 DOI: 10.1016/j.cellsig.2021.109972] [Reference Citation Analysis]
142 Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Bräu N; Liver Cancer in HIV and ITA.LI.CA Study Groups. Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. J Clin Oncol 2019;37:296-304. [PMID: 30562130 DOI: 10.1200/JCO.18.00885] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
143 Khan SA, McClements S, Reccia I, Evans J, Pai M, Sharma R. The next generation of hepatocellular cancer experts: what do they think? Hepat Oncol 2016;3:213-5. [PMID: 30191043 DOI: 10.2217/hep-2017-0003] [Reference Citation Analysis]
144 Kim H, Ahn SW, Hong SK, Yoon KC, Kim H, Choi YR, Lee HW, Yi N, Lee K, Suh K. Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. British Journal of Surgery 2017;104:1045-52. [DOI: 10.1002/bjs.10541] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
145 Minami Y, Kudo M. Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need. Hepatobiliary Surg Nutr 2019;8:414-6. [PMID: 31489318 DOI: 10.21037/hbsn.2019.04.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
146 Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 2015;61:526-36. [PMID: 25212123 DOI: 10.1002/hep.27431] [Cited by in Crossref: 193] [Cited by in F6Publishing: 166] [Article Influence: 27.6] [Reference Citation Analysis]
147 Bhoori S, Mazzaferro V. Current challenges in liver transplantation for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:867-79. [DOI: 10.1016/j.bpg.2014.08.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
148 Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27213358 DOI: 10.3390/ijms17050774] [Cited by in Crossref: 248] [Cited by in F6Publishing: 242] [Article Influence: 41.3] [Reference Citation Analysis]
149 Sun G, Sun K, Shen C. Human nuclear receptors (NRs) genes have prognostic significance in hepatocellular carcinoma patients. World J Surg Oncol 2021;19:137. [PMID: 33941198 DOI: 10.1186/s12957-021-02246-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Mao J, Wang D, Wang Z, Tian W, Li X, Duan J, Wang Y, Yang H, You L, Cheng Y, Bian J, Chen Z, Yang Y. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway. Cancer Lett 2016;380:134-43. [PMID: 27349166 DOI: 10.1016/j.canlet.2016.06.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
151 Herraez E, Sanchez-Vicente L, Macias RIR, Briz O, Marin JJG. Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1. Oncotarget 2017;8:34617-29. [PMID: 28423714 DOI: 10.18632/oncotarget.16119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
152 Song J, Guan Z, Song C, Li M, Gao Z, Zhao Y. Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways. Mol Med Rep 2021;23:429. [PMID: 33846786 DOI: 10.3892/mmr.2021.12068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
153 He XX, Shi LL, Qiu MJ, Li QT, Wang MM, Xiong ZF, Yang SL. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. Biochem Biophys Res Commun 2018;504:878-84. [PMID: 30219235 DOI: 10.1016/j.bbrc.2018.08.203] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
154 Aboelfotoh AO, Foda EM, Elghandour AM, Teama NM, Abouzein RA, Mohamed GA. Talin-1; other than a potential marker for hepatocellular carcinoma diagnosis. Arab J Gastroenterol 2020;21:80-4. [PMID: 32439236 DOI: 10.1016/j.ajg.2020.04.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
155 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
156 Huo J, Cai J, Wu L. Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma. Cancer Med 2022. [PMID: 35651292 DOI: 10.1002/cam4.4858] [Reference Citation Analysis]
157 Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, Shi X. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res 2018;37:324. [PMID: 30591064 DOI: 10.1186/s13046-018-0965-2] [Cited by in Crossref: 97] [Cited by in F6Publishing: 111] [Article Influence: 24.3] [Reference Citation Analysis]
158 Pohlman RM, Varghese T, Jiang J, Ziemlewicz TJ, Alexander ML, Wergin KL, Hinshaw JL, Lubner MG, Wells SA, Lee FT Jr. Comparison of Displacement Tracking Algorithms for in Vivo Electrode Displacement Elastography. Ultrasound Med Biol 2019;45:218-32. [PMID: 30318122 DOI: 10.1016/j.ultrasmedbio.2018.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
159 Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, Diaz A, Vilana R, Darnell A, Varela M. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726. [PMID: 27084592 DOI: 10.1016/j.jhep.2016.04.008] [Cited by in Crossref: 612] [Cited by in F6Publishing: 581] [Article Influence: 102.0] [Reference Citation Analysis]
160 Hu B, Cheng JW, Hu JW, Li H, Ma XL, Tang WG, Sun YF, Guo W, Huang A, Zhou KQ, Gao PT, Cao Y, Qiu SJ, Zhou J, Fan J, Yang XR. KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. J Cancer 2019;10:3914-25. [PMID: 31417635 DOI: 10.7150/jca.31448] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
161 Rui S, Yan J, Zhang H, Wang Z, Zhou W. Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy. Medicine (Baltimore) 2017;96:e7608. [PMID: 28746212 DOI: 10.1097/MD.0000000000007608] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
162 Bai N, Peng E, Qiu X, Lyu N, Zhang Z, Tao Y, Li X, Wang Z. circFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging miR-346. J Exp Clin Cancer Res 2018;37:172. [PMID: 30053867 DOI: 10.1186/s13046-018-0838-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 83] [Article Influence: 18.3] [Reference Citation Analysis]
163 Yang J, Wang J, Luo J. Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib. Pathology - Research and Practice 2019;215:152565. [DOI: 10.1016/j.prp.2019.152565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
164 Xie ZR, Luo YL. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Med Oncol 2015;32:88. [PMID: 25707770 DOI: 10.1007/s12032-015-0534-x] [Reference Citation Analysis]
165 Zhao QJ, Zhang J, Xu L, Liu FF. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol 2018; 24(30): 3426-3439 [PMID: 30122881 DOI: 10.3748/wjg.v24.i30.3426] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
166 Ye J, Wu S, Pan S, Huang J, Ge L. Risk scoring based on expression of long non‑coding RNAs can effectively predict survival in hepatocellular carcinoma patients with or without fibrosis. Oncol Rep 2020;43:1451-66. [PMID: 32323856 DOI: 10.3892/or.2020.7528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
167 Chen J, Xia H, Zhang X, Karthik S, Pratap SV, Ooi LL, Hong W, Hui KM. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma. J Hepatol. 2015;62:1287-1295. [PMID: 25617497 DOI: 10.1016/j.jhep.2015.01.014] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 8.7] [Reference Citation Analysis]
168 Du Q, Li L, Liu Y, Zeng J, Li J, Zheng C, Zhou G, Yang X. Fabrication of inherently radiopaque BaSO 4 @BaAlg microspheres by a one-step electrospraying method for embolization. J Mater Chem B 2018;6:3522-30. [DOI: 10.1039/c8tb00542g] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
169 Wang Y, Hou J. Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. Hepatol Int 2016;10:448-61. [DOI: 10.1007/s12072-015-9695-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
170 Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 2014;20:1138-46. [PMID: 25216638 DOI: 10.1038/nm.3679] [Cited by in Crossref: 171] [Cited by in F6Publishing: 160] [Article Influence: 21.4] [Reference Citation Analysis]
171 Zou W, Cui J, Ren Z, Leng Y. NRAGE is a potential diagnostic biomarker of hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e13411. [PMID: 30508943 DOI: 10.1097/MD.0000000000013411] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
172 Wu W, Wang Q, Han D, Li J, Nie Y, Guo D, Yang L, Tao K, Zhang X, Dou K. Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection. Cancer Cell Int 2021;21:500. [PMID: 34535132 DOI: 10.1186/s12935-021-02204-3] [Reference Citation Analysis]
173 Fabregat I, Moreno-càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, ten Dijke P; the IT-LIVER Consortium. TGF-β signalling and liver disease. FEBS J 2016;283:2219-32. [DOI: 10.1111/febs.13665] [Cited by in Crossref: 247] [Cited by in F6Publishing: 243] [Article Influence: 41.2] [Reference Citation Analysis]
174 Bai Y, Wang J, Han J, Xie X, Ji C, Yin J, Chen L, Wang C, Jiang X, Qi W, Jiang H. BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo: ROLE OF BCL2L10 IN LIVER CANCER. Mol Carcinog 2017;56:1137-49. [DOI: 10.1002/mc.22580] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
175 Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract 2017;71:e12972. [DOI: 10.1111/ijcp.12972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
176 Quan B, Zhang WG, Serenari M, Liang L, Xing H, Li C, Wang MD, Lau WY, Schwartz M, Pawlik TM, Cescon M, Wu MC, Shen F, Yang T. A novel online calculator to predict perioperative blood transfusion in patients undergoing liver resection for hepatocellular carcinoma: an international multicenter study. HPB (Oxford) 2020;22:1711-21. [PMID: 32340856 DOI: 10.1016/j.hpb.2020.03.018] [Reference Citation Analysis]
177 Matsushima-Nishiwaki R, Toyoda H, Nagasawa T, Yasuda E, Chiba N, Okuda S, Maeda A, Kaneoka Y, Kumada T, Kozawa O. Phosphorylated Heat Shock Protein 20 (HSPB6) Regulates Transforming Growth Factor-α-Induced Migration and Invasion of Hepatocellular Carcinoma Cells. PLoS One 2016;11:e0151907. [PMID: 27046040 DOI: 10.1371/journal.pone.0151907] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
178 Lee SH, Jin YJ, Lee JW. Survival benefit of radiofrequency ablation for solitary (3-5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry. Medicine (Baltimore) 2017;96:e8486. [PMID: 29095307 DOI: 10.1097/MD.0000000000008486] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
179 Chen Z, Lu X, Jia D, Jing Y, Chen D, Wang Q, Zhao F, Li J, Yao M, Cong W, He X. Hepatic SMARCA4 predicts HCC recurrence and promotes tumour cell proliferation by regulating SMAD6 expression. Cell Death Dis 2018;9:59. [PMID: 29352111 DOI: 10.1038/s41419-017-0090-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
180 Lu Q, Li J, Cao H, Lv C, Wang X, Cao S. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep 2020;40:BSR20192424. [PMID: 32039435 DOI: 10.1042/BSR20192424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
181 Qi X, Zhang X, Li Z, Hui J, Xiang Y, Chen J, Zhao J, Li J, Qi FZ, Xu Y. HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma. Oncotarget 2016;7:62789-96. [PMID: 27566593 DOI: 10.18632/oncotarget.11558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
182 Zhen H, Qian X, Fu X, Chen Z, Zhang A, Shi L. Regulation of Shaoyao Ruangan Mixture on Intestinal Flora in Mice With Primary Liver Cancer. Integr Cancer Ther 2019;18:1534735419843178. [PMID: 31006277 DOI: 10.1177/1534735419843178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
183 Toniutto P, Zanetto A, Ferrarese A, Burra P. Current challenges and future directions for liver transplantation. Liver Int. 2017;37:317-327. [PMID: 27634369 DOI: 10.1111/liv.13255] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
184 Wang Y, Shang W, Zhong H, Luo T, Niu M, Xu K, Tian J. Tumor Vessel Targeted Self-Assemble Nanoparticles for Amplification and Prediction of the Embolization Effect in Hepatocellular Carcinoma. ACS Nano 2020;14:14907-18. [PMID: 33111520 DOI: 10.1021/acsnano.0c04341] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
185 Porcu C, Antonucci L, Barbaro B, Illi B, Nasi S, Martini M, Licata A, Miele L, Grieco A, Balsano C. Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma. Oncotarget 2018;9:9325-43. [PMID: 29507693 DOI: 10.18632/oncotarget.24282] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
186 Volpi S, Tsoumakidou G, Loriaud A, Hocquelet A, Duran R, Denys A. Electromagnetic navigation system combined with High-Frequency-Jet-Ventilation for CT-guided hepatic ablation of small US-Undetectable and difficult to access lesions. International Journal of Hyperthermia 2019;36:1050-6. [DOI: 10.1080/02656736.2019.1671612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
187 Fang Z, Shen Y, Gao D. Stimulus-responsive nanocarriers for targeted drug delivery. New J Chem 2021;45:4534-44. [DOI: 10.1039/d0nj05169a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
188 Kroh A, Walter J, Schüler H, Nolting J, Eickhoff R, Heise D, Neumann UP, Cramer T, Ulmer TF, Fragoulis A. A Newly Established Murine Cell Line as a Model for Hepatocellular Cancer in Non-Alcoholic Steatohepatitis. Int J Mol Sci 2019;20:E5658. [PMID: 31726709 DOI: 10.3390/ijms20225658] [Reference Citation Analysis]
189 Huang F, Chen J, Lan R, Wang Z, Chen R, Lin J, Zhang L, Fu L. δ-Catenin peptide vaccines repress hepatocellular carcinoma growth via CD8+ T cell activation. Oncoimmunology 2018;7:e1450713. [PMID: 30221043 DOI: 10.1080/2162402X.2018.1450713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
190 Liu F, Qian Y. The role of CD133 in hepatocellular carcinoma. Cancer Biol Ther 2021;22:291-300. [PMID: 33899676 DOI: 10.1080/15384047.2021.1916381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Jing CY, Fu YP, Zheng SS, Yi Y, Shen HJ, Huang JL, Xu X, Lin JJ, Zhou J, Fan J, Ren ZG, Qiu SJ, Zhang BH. Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection. Medicine (Baltimore) 2017;96:e6140. [PMID: 28296727 DOI: 10.1097/MD.0000000000006140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
192 Xia H, Chen J, Shi M, Gao H, Sekar K, Seshachalam VP, Ooi LLP, Hui KM. EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma. Journal of Hepatology 2015;63:863-73. [DOI: 10.1016/j.jhep.2015.05.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
193 Kanda M, Murotani K, Sugimoto H, Miwa T, Umeda S, Suenaga M, Hayashi M, Hattori N, Tanaka C, Kobayashi D, Yamada S, Fujiwara M, Kodera Y. An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget 2017;8:71070-9. [PMID: 29050343 DOI: 10.18632/oncotarget.20369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
194 Yamashita YI, Hayashi H, Imai K, Okabe H, Nakagawa S, Kitamura F, Uemura N, Nakao Y, Yusa T, Itoyama R, Yamao T, Umesaki N, Miyata T, Chikamoto A, Shimokawa M, Baba H. Perioperative Allogeneic Blood Transfusion Does not Influence Patient Survival After Hepatectomy for Hepatocellular Carcinoma: A Propensity Score Matching Analysis. World J Surg 2019;43:2894-901. [PMID: 31312946 DOI: 10.1007/s00268-019-05085-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
195 Zhong JH, Ke Y, Wang YY, Li LQ. Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension. Gut 2015;64:520-1. [PMID: 25187522 DOI: 10.1136/gutjnl-2014-308139] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
196 Meng FD, Wei JC, Qu K, Wang ZX, Wu QF, Tai MH, Liu HC, Zhang RY, Liu C. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(1): 196-213 [PMID: 25574092 DOI: 10.3748/wjg.v21.i1.196] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
197 Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer 2019;8:281-94. [PMID: 31602371 DOI: 10.1159/000490260] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
198 Chen ZZ, Huang L, Wu YH, Zhai WJ, Zhu PP, Gao YF. LncSox4 promotes the self-renewal of liver tumour-initiating cells through Stat3-mediated Sox4 expression. Nat Commun. 2016;7:12598. [PMID: 27553854 DOI: 10.1038/ncomms12598] [Cited by in Crossref: 95] [Cited by in F6Publishing: 110] [Article Influence: 15.8] [Reference Citation Analysis]
199 Heinrich S, Sprinzl M, Schmidtmann I, Heil E, Koch S, Czauderna C, Heinrich B, Philippe P Diggs L, Wörns MA, Kloeckner R, Galle PR, Marquardt JU, Weinmann A. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 2020;8:444-52. [PMID: 32213028 DOI: 10.1177/2050640620904524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
200 Yang H, Han P, Huang M, Yue X, Wu L, Li X, Fan W, Li Q, Ma G, Lei P. The role of gadoxetic acid-enhanced MRI features for predicting microvascular invasion in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2022;47:948-56. [PMID: 34962593 DOI: 10.1007/s00261-021-03392-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
201 Zhou Q, An Y, Liu T, Liu Z, Li R, Wang C, Zhou F, Liu C, Zhu K. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation. Int J Hyperthermia 2022;39:97-107. [PMID: 34979845 DOI: 10.1080/02656736.2021.2021303] [Reference Citation Analysis]
202 Su J, Huang Y, Wang Y, Li R, Deng W, Zhang H, Xiong H. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma. Cancer Cell Int 2022;22:67. [PMID: 35139863 DOI: 10.1186/s12935-022-02485-2] [Reference Citation Analysis]
203 Deng M, Li S, Mei J, Lin W, Zou J, Wei W, Guo R. High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. Genes (Basel) 2021;12:876. [PMID: 34200261 DOI: 10.3390/genes12060876] [Reference Citation Analysis]
204 Kozbial K, Moser S, Schwarzer R, Laferl H, Al-zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-radosalvjevic M, Trauner M, Hofer H, Ferenci P. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. Journal of Hepatology 2016;65:856-8. [DOI: 10.1016/j.jhep.2016.06.009] [Cited by in Crossref: 139] [Cited by in F6Publishing: 146] [Article Influence: 23.2] [Reference Citation Analysis]
205 Zhang XF, Chao J, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Jiang SS, Chen CL, Zhang HX, Xia JC. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget 2015;6:40920-33. [PMID: 26506518 DOI: 10.18632/oncotarget.5712] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
206 Lu DH, Lv WW, Li WX, Gao YD. High PKM2 expression is independently correlated with decreased overall survival in hepatocellular carcinoma. Oncol Lett 2018;16:3603-10. [PMID: 30127967 DOI: 10.3892/ol.2018.9100] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
207 Gowhari Shabgah A, Ezzatifar F, Aravindhan S, Olegovna Zekiy A, Ahmadi M, Gheibihayat SM, Gholizadeh Navashenaq J. Shedding more light on the role of Midkine in hepatocellular carcinoma: New perspectives on diagnosis and therapy. IUBMB Life 2021;73:659-69. [PMID: 33625758 DOI: 10.1002/iub.2458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Lin W, Zhao Z, Ni Z, Zhao Y, Du W, Chen S. IFI16 restoration in hepatocellular carcinoma induces tumour inhibition via activation of p53 signals and inflammasome. Cell Prolif 2017;50. [PMID: 28990231 DOI: 10.1111/cpr.12392] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
209 Wang XP, Wang QX, Lin HP, Xu B, Zhao Q, Chen K. Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific anti-tumor immunity. Oncotarget. 2016;7:71274-71284. [PMID: 27713135 DOI: 10.18632/oncotarget.12464] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
210 Wang Y, Luo S, Jin G, Fu R, Yu Z, Zhang J. Preoperative clinical-radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using $$^{18}$$F-FDG PET/CT. BMC Med Imaging 2022;22. [DOI: 10.1186/s12880-022-00796-4] [Reference Citation Analysis]
211 Zou J, Li S, Wang Q, Mei J, Lu L, Lin W, Wen Y, Li Y, Wei W, Guo R. Surgical strategies for hepatocellular carcinoma located in the left lateral lobe: A propensity score-matched and prognostic nomogram study. Cancer Med 2021;10:3274-87. [PMID: 33932132 DOI: 10.1002/cam4.3894] [Reference Citation Analysis]
212 Berzigotti A, Reig M, Bruix J. Reply: To PMID 25212123. Hepatology 2015;62:978-9. [PMID: 25598299 DOI: 10.1002/hep.27701] [Reference Citation Analysis]
213 Peng WX, Xiong EM, Ge L, Wan YY, Zhang CL, Du FY, Xu M, Bhat RA, Jin J, Gong AH. Egr-1 promotes hypoxia-induced autophagy to enhance chemo-resistance of hepatocellular carcinoma cells. Exp Cell Res 2016;340:62-70. [PMID: 26708617 DOI: 10.1016/j.yexcr.2015.12.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
214 Shen J, Wang WS, Zhu XL, Ni CF. High Epithelial Cell Adhesion Molecule-Positive Circulating Tumor Cell Count Predicts Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization. J Vasc Interv Radiol. 2018;29:1678-1684. [PMID: 30392801 DOI: 10.1016/j.jvir.2018.07.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
215 Lekht I, Gulati M, Nayyar M, Katz MD, Ter-Oganesyan R, Marx M, Cen SY, Grant E. Role of contrast-enhanced ultrasound (CEUS) in evaluation of thermal ablation zone. Abdom Radiol (NY) 2016;41:1511-21. [PMID: 26969495 DOI: 10.1007/s00261-016-0700-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
216 Li Z, Lei Z, Xia Y, Li J, Wang K, Zhang H, Wan X, Yang T, Zhou W, Wu M, Pawlik TM, Lau WY, Shen F. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surg 2018;153:e182721. [PMID: 30073257 DOI: 10.1001/jamasurg.2018.2721] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
217 Zhou Q, Tuo F, Li R, Wang X, Wang J, Huang Z, Chen M, Huang J. Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. Front Oncol 2020;10:578763. [PMID: 33251141 DOI: 10.3389/fonc.2020.578763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
218 Zheng L, Zhuang C, Zhao J, Ming L. Functional miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms and the susceptibility to hepatocellular carcinoma: An updated meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:664-76. [PMID: 28499985 DOI: 10.1016/j.clinre.2017.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
219 Wang J, Gong L, Zhu SJ, Zhu Q, Yao L, Han XJ, Zhang JR, Li YH, Zhang W. The Human Homolog of Drosophila Headcase Acts as a Tumor Suppressor through Its Blocking Effect on the Cell Cycle in Hepatocellular Carcinoma. PLoS One 2015;10:e0137579. [PMID: 26356417 DOI: 10.1371/journal.pone.0137579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
220 Lu JW, Lin LI, Sun Y, Liu D, Gong Z. Effect of Lipopolysaccharides on Liver Tumor Metastasis of twist1a/krasV12 Double Transgenic Zebrafish. Biomedicines 2022;10:95. [PMID: 35052775 DOI: 10.3390/biomedicines10010095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Huang Z, Liang B, Xiong M, Dong K, Zhang Z, Zhang E, Li C, Chen X. Severity of cirrhosis should determine the operative modality for patients with early hepatocellular carcinoma and compensated liver function. Surgery 2016;159:621-31. [DOI: 10.1016/j.surg.2015.09.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
222 Wang R, Yu Z, Chen F, Liao C, Wang Q, Huang X. Overexpression of ARID4B predicts poor survival in patients with hepatocellular carcinoma. Hum Pathol 2018;73:114-21. [PMID: 29288040 DOI: 10.1016/j.humpath.2017.12.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
223 Hu Q, Wang K, Sun X, Li Y, Fu Q, Liang T, Tang G. A redox-sensitive, oligopeptide-guided, self-assembling, and efficiency-enhanced (ROSE) system for functional delivery of microRNA therapeutics for treatment of hepatocellular carcinoma. Biomaterials 2016;104:192-200. [DOI: 10.1016/j.biomaterials.2016.07.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
224 Tian YD, Lin S, Yang PT, Bai MH, Jin YY, Min WL, Ma HB, Wang BF. Saikosaponin-d Increases the Radiosensitivity of Hepatoma Cells by Adjusting Cell Autophagy. J Cancer 2019;10:4947-53. [PMID: 31598167 DOI: 10.7150/jca.30286] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
225 Öksüz Z, Üçbilek E, Serin MS, Yaraş S, Temel GO, Sezgin O. Circulating vascular adhesion protein-1(VAP-1): a possible biomarker for liver fibrosis associated with chronic hepatitis B and C. Braz J Microbiol 2020;51:1757-63. [PMID: 32959205 DOI: 10.1007/s42770-020-00379-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
226 Zhu P, Wang Y, Wu J, Huang G, Liu B, Ye B, Du Y, Gao G, Tian Y, He L, Fan Z. LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. Nat Commun 2016;7:13608. [PMID: 27905400 DOI: 10.1038/ncomms13608] [Cited by in Crossref: 153] [Cited by in F6Publishing: 165] [Article Influence: 25.5] [Reference Citation Analysis]
227 Bazine A, Fetohi M, Berri MA, Essaadi I, Elbakraoui K, Ichou M, Errihani H. Spinal cord ischemia secondary to transcatheter arterial chemoembolization for hepatocellular carcinoma. Case Rep Gastroenterol. 2014;8:264-269. [PMID: 25408628 DOI: 10.1159/000368075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
228 Bai T, Chen J, Xie ZB, Wu FX, Wang SD, Liu JJ, Li LQ. The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus. Onco Targets Ther. 2016;9:3841-3848. [PMID: 27390524 DOI: 10.2147/ott.s104307] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
229 Sun Q, Yu R, Wang C, Yao J, Zhang L. Circular RNA circ-CSPP1 regulates CCNE2 to facilitate hepatocellular carcinoma cell growth via sponging miR-577. Cancer Cell Int 2020;20:202. [PMID: 32514247 DOI: 10.1186/s12935-020-01287-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
230 Wan J, Liu H, Yang L, Ma L, Liu J, Ming L. JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4. Int J Cancer 2019;144:2489-500. [PMID: 30125344 DOI: 10.1002/ijc.31816] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
231 Chen Z, Lu X, Wang Z, Jin G, Wang Q, Chen D, Chen T, Li J, Fan J, Cong W. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Oncotarget. 2015;6:2538-2548. [PMID: 25576919 DOI: 10.18632/oncotarget.2991] [Cited by in Crossref: 22] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
232 Li L, Yu S, Hu Q, Hai Y, Li Y. Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy. Int J Biol Sci 2021;17:3133-44. [PMID: 34421355 DOI: 10.7150/ijbs.62393] [Reference Citation Analysis]
233 Zhou L, Zhu Y. The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis. International Journal of Surgery 2018;56:274-80. [DOI: 10.1016/j.ijsu.2018.06.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
234 Sun B, Chen Y, Xiang T, Zhang L, Chen Z, Zhang S, Zhou H, Chen S. The Chinese Herb Jianpijiedu Contributes to the Regulation of OATP1B2 and ABCC2 in a Rat Model of Orthotopic Transplantation Liver Cancer Pretreated with Food Restriction and Diarrhea. Biomed Res Int 2015;2015:752850. [PMID: 26665149 DOI: 10.1155/2015/752850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
235 Qin W, Wang L, Hu B, Leng S, Tian H, Luo H, Yao J, Chen X, Wu C, Chen G, Yang Y. A Novel Score Predicts HBV-Related Hepatocellular Carcinoma Recurrence After Hepatectomy: a Retrospective Multicenter Study. J Gastrointest Surg 2019;23:922-32. [PMID: 30446938 DOI: 10.1007/s11605-018-4037-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
236 Lu SD, Wang YY, Peng NF, Peng YC, Zhong JH, Qin HG, Xiang BD, You XM, Ma L, Li LQ. Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma. Medicine (Baltimore) 2016;95:e2722. [PMID: 26844516 DOI: 10.1097/MD.0000000000002722] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
237 Xu X, Chen R, Chen Q, An K, Ding L, Zhang L, Wang F, Deng Y. Efficacy of traditional herbal medicine versus transcatheter arterial chemoembolization in postsurgical patients with hepatocellular carcinoma: A retrospective study. Complement Ther Clin Pract 2021;43:101359. [PMID: 33711747 DOI: 10.1016/j.ctcp.2021.101359] [Reference Citation Analysis]
238 Shang H, Wu B, Liang X, Sun Y, Han X, Zhang L, Wang Q, Cheng W. Evaluation of therapeutic effect of targeting nanobubbles conjugated with NET-1 siRNA by shear wave elastography: an in vivo study of hepatocellular carcinoma bearing mice model. Drug Deliv 2019;26:944-51. [PMID: 31544556 DOI: 10.1080/10717544.2019.1667450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
239 Liao R, Li D, Du C, Li M. Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. J Gastrointest Surg 2018;22:1679-87. [DOI: 10.1007/s11605-018-3810-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
240 Du B, Liao H, Zhang S. Expression Pattern and Prognostic Utility of PME-1 in Patients with Hepatocellular Carcinoma. Cancer Manag Res 2020;12:2937-45. [PMID: 32431540 DOI: 10.2147/CMAR.S252873] [Reference Citation Analysis]
241 Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol 2021;11:726213. [PMID: 34900676 DOI: 10.3389/fonc.2021.726213] [Reference Citation Analysis]
242 Gu Y, Wang X, Liu H, Li G, Yu W, Ma Q. SET7/9 promotes hepatocellular carcinoma progression through regulation of E2F1. Oncol Rep 2018;40:1863-74. [PMID: 30106440 DOI: 10.3892/or.2018.6621] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
243 Li H, Liu J, Chen M, Li H, Long L. Therapeutic Evaluation of Radiotherapy with Contrast-Enhanced Ultrasound in Non-Resectable Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis. Med Sci Monit 2018;24:8183-9. [PMID: 30426970 DOI: 10.12659/MSM.911073] [Reference Citation Analysis]
244 Zhang Y, Wei C, Guo CC, Bi RX, Xie J, Guan DH, Yang CH, Jiang YH. Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis. Oncotarget 2017;8:107237-57. [PMID: 29291025 DOI: 10.18632/oncotarget.20883] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
245 Xiang XH, Yang L, Zhang X, Ma XH, Miao RC, Gu JX, Fu YN, Yao Q, Zhang JY, Liu C, Lin T, Qu K. Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma. World J Gastroenterol 2019; 25(14): 1715-1728 [PMID: 31011256 DOI: 10.3748/wjg.v25.i14.1715] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
246 Pang Q, Bi JB, Xu XS, Liu SS, Zhang JY, Zhou YY, Qu K, Liu C. King's score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015;27:1337-1346. [PMID: 26275082 DOI: 10.1097/meg.0000000000000452] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
247 Li X, Li M, Chen J, Dai H, Wang L, Xiong Y, Zhong Y, Zhang L. SAMMSON drives the self-renewal of liver tumor initiating cells through EZH2-dependent Wnt/β-catenin activation. Oncotarget 2017;8:103785-96. [PMID: 29262600 DOI: 10.18632/oncotarget.21792] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
248 Nguyen Ho-bouldoires TH, Clapéron A, Mergey M, Wendum D, Desbois-mouthon C, Tahraoui S, Fartoux L, Chettouh H, Merabtene F, Scatton O, Gaestel M, Praz F, Housset C, Fouassier L. Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells. Free Radical Biology and Medicine 2015;89:34-46. [DOI: 10.1016/j.freeradbiomed.2015.07.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
249 Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One. 2016;11:e0155800. [PMID: 27219517 DOI: 10.1371/journal.pone.0155800] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
250 Kikuchi A, Monga SP. PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer. Gene Expr 2015;16:109-27. [PMID: 25700367 DOI: 10.3727/105221615X14181438356210] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
251 Chen Z, Liu Y, Yao L, Guo S, Gao Y, Zhu P. The long noncoding RNA lncZic2 drives the self-renewal of liver tumor-initiating cells via the protein kinase C substrates MARCKS and MARCKSL1. J Biol Chem 2018;293:7982-92. [PMID: 29588366 DOI: 10.1074/jbc.RA117.001321] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
252 Luo W, Zhu X, Liu W, Ren Y, Bei C, Qin L, Miao X, Tang F, Tang G, Tan S. MYC associated zinc finger protein promotes the invasion and metastasis of hepatocellular carcinoma by inducing epithelial mesenchymal transition. Oncotarget 2016;7:86420-32. [PMID: 27861158 DOI: 10.18632/oncotarget.13416] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
253 Nakanishi H, Kurosaki M, Tsuchiya K, Yasui Y, Higuchi M, Yoshida T, Komiyama Y, Takaura K, Hayashi T, Kuwabara K, Nakakuki N, Takada H, Ueda M, Tamaki N, Suzuki S, Itakura J, Takahashi Y, Izumi N. Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer 2016;5:257-68. [PMID: 27781198 DOI: 10.1159/000449337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
254 Li L, Li B, Zhang M. HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion. Medicine (Baltimore) 2019;98:e16308. [PMID: 31277172 DOI: 10.1097/MD.0000000000016308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
255 Zhang Y, Zhu Z, Huang S, Zhao Q, Huang C, Tang Y, Sun C, Zhang Z, Wang L, Chen H, Chen M, Ju W, He X. lncRNA XIST regulates proliferation and migration of hepatocellular carcinoma cells by acting as miR-497-5p molecular sponge and targeting PDCD4. Cancer Cell Int 2019;19:198. [PMID: 31384173 DOI: 10.1186/s12935-019-0909-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
256 Yu S, Zhou X, Xiang H, Wang S, Cui Z, Zhou J. Resveratrol Reduced Liver Damage After Liver Resection in a Rat Model by Upregulating Sirtuin 1 (SIRT1) and Inhibiting the Acetylation of High Mobility Group Box 1 (HMGB1). Med Sci Monit 2019;25:3212-20. [PMID: 31041919 DOI: 10.12659/MSM.913937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
257 You N, Li J, Huang X, Wu K, Tang Y, Wang L, Li H, Mi N, Zheng L. COMMD7 promotes hepatocellular carcinoma through regulating CXCL10. Biomed Pharmacother 2017;88:653-7. [PMID: 28142122 DOI: 10.1016/j.biopha.2017.01.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
258 Nio K, Yamashita T, Okada H, Kondo M, Hayashi T, Hara Y, Nomura Y, Zeng SS, Yoshida M, Hayashi T. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma. J Hepatol. 2015;63:1164-1172. [PMID: 26095183 DOI: 10.1016/j.jhep.2015.06.009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
259 Li L, Xu L, Wen T, Wu H, Wang W, Yang J, Chen Z, Wei Y, Xu M, Li B, Zhang M. Poor Prognoses of Young Hepatocellular Carcinoma Patients with Microvascular Invasion: A Propensity Score Matching Cohort Study. Gastroenterol Res Pract 2020;2020:4691425. [PMID: 32148477 DOI: 10.1155/2020/4691425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
260 Huang P, Xu M, Han H, Zhao X, Li MD, Yang Z. Integrative Analysis of Epigenome and Transcriptome Data Reveals Aberrantly Methylated Promoters and Enhancers in Hepatocellular Carcinoma. Front Oncol 2021;11:769390. [PMID: 34858848 DOI: 10.3389/fonc.2021.769390] [Reference Citation Analysis]
261 Zhang ZY, Dong KS, Zhang EL, Zhang LW, Chen XP, Dong HH. Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e18362. [PMID: 31852141 DOI: 10.1097/MD.0000000000018362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
262 Cheng Z, He L, Guo Y, Song Y, Song S, Zhang L. The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. World J Surg Oncol 2020;18:243. [PMID: 32917226 DOI: 10.1186/s12957-020-02017-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Gu JJ, Yao M, Yang J, Cai Y, Zheng WJ, Wang L, Yao DB, Yao DF. Mitochondrial carnitine palmitoyl transferase-II inactivity aggravates lipid accumulation in rat hepatocarcinogenesis. World J Gastroenterol 2017; 23(2): 256-264 [PMID: 28127199 DOI: 10.3748/wjg.v23.i2.256] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
264 Wang D, Han S, Peng R, Wang X, Yang XX, Yang RJ, Jiao CY, Ding D, Ji GW, Li XC. FAM83D activates the MEK/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma. Biochem Biophys Res Commun 2015;458:313-20. [PMID: 25646692 DOI: 10.1016/j.bbrc.2015.01.108] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
265 Yao T, Chen Q, Shao Z, Song Z, Fu L, Xiao B. Circular RNA 0068669 as a new biomarker for hepatocellular carcinoma metastasis. J Clin Lab Anal 2018;32:e22572. [PMID: 29785842 DOI: 10.1002/jcla.22572] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
266 Pohlman RM, Varghese T. Dictionary Representations for Electrode Displacement Elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2018;65:2381-9. [PMID: 30296219 DOI: 10.1109/TUFFC.2018.2874181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
267 Xia Y, Zhen L, Li H, Wang S, Chen S, Wang C, Yang X. MIRLET7BHG promotes hepatocellular carcinoma progression by activating hepatic stellate cells through exosomal SMO to trigger Hedgehog pathway. Cell Death Dis 2021;12:326. [PMID: 33771969 DOI: 10.1038/s41419-021-03494-1] [Reference Citation Analysis]
268 Liu L, Zhang QS, Pan LH, Zhong JH, Qin ZM, Wang YY, Qin HG, Gong WF, Qi LN, Xiang BD, Li LQ. Subclassification of patients with solitary hepatocellular carcinoma based on post-hepatectomy survival: a large retrospective study. Tumour Biol 2016;37:5327-35. [PMID: 26561470 DOI: 10.1007/s13277-015-4387-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
269 Shao J, Cao J, Liu Y, Mei H, Zhang Y, Xu W. MicroRNA-519a promotes proliferation and inhibits apoptosis of hepatocellular carcinoma cells by targeting FOXF2. FEBS Open Bio 2015;5:893-9. [PMID: 26693396 DOI: 10.1016/j.fob.2015.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
270 Ou MC, Liu YS, Chuang MT, Lin CY, Huang LT, Lin CY. Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma. Clin Radiol 2019;74:295-300. [PMID: 30635122 DOI: 10.1016/j.crad.2018.12.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
271 Wu JY, Wang ZX, Zhang G, Lu X, Qiang GH, Hu W, Ji AL, Wu JH, Jiang CP. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy. Int J Nanomedicine 2018;13:1265-80. [PMID: 29551896 DOI: 10.2147/IJN.S156328] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
272 Qi LN, Ma L, Chen YY, Chen ZS, Zhong JH, Gong WF, Lu Y, Xiang BD, Li LQ. Outcomes of anatomical versus non-anatomical resection for hepatocellular carcinoma according to circulating tumour-cell status. Ann Med 2020;52:21-31. [PMID: 31876201 DOI: 10.1080/07853890.2019.1709655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Qi Q, Qian X, Zhu X, Cai J, Xia R, Zhang Q. Perioperative Transfusion is Related to the Length of Hospital Stays in Primary Liver Cancer Patients. Cancer Manag Res 2021;13:4947-54. [PMID: 34188547 DOI: 10.2147/CMAR.S296022] [Reference Citation Analysis]
274 Renzulli M, Mottola M, Coppola F, Cocozza MA, Malavasi S, Cattabriga A, Vara G, Ravaioli M, Cescon M, Vasuri F, Golfieri R, Bevilacqua A. Automatically Extracted Machine Learning Features from Preoperative CT to Early Predict Microvascular Invasion in HCC: The Role of the Zone of Transition (ZOT). Cancers 2022;14:1816. [DOI: 10.3390/cancers14071816] [Reference Citation Analysis]
275 Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803-810. [PMID: 25190127 DOI: 10.1245/s10434-014-4048-0] [Cited by in Crossref: 199] [Cited by in F6Publishing: 207] [Article Influence: 24.9] [Reference Citation Analysis]
276 Zheng N, Wei X, Zhang D, Chai W, Che M, Wang J, Du B. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Medicine (Baltimore). 2016;95:e3959. [PMID: 27367992 DOI: 10.1097/md.0000000000003959] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
277 Xie L, Li M, Liu D, Wang X, Wang P, Dai H, Yang W, Liu W, Hu X, Zhao M. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway. Molecules 2019;24:E393. [PMID: 30678274 DOI: 10.3390/molecules24030393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
278 Li Y, Zhuang W, Huang M, Li X. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma. Biochem Biophys Res Commun 2019;514:1051-7. [PMID: 31097223 DOI: 10.1016/j.bbrc.2019.05.042] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
279 Li J, Zhu Y. Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins. Front Cell Dev Biol 2020;8:548335. [PMID: 33117795 DOI: 10.3389/fcell.2020.548335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
280 Schipilliti FM, Garajová I, Rovesti G, Balsano R, Piacentini F, Dominici M, Gelsomino F. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals (Basel) 2021;14:43. [PMID: 33429973 DOI: 10.3390/ph14010043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
281 Pohlman RM, Varghese T. Physiological Motion Reduction Using Lagrangian Tracking for Electrode Displacement Elastography. Ultrasound Med Biol 2020;46:766-81. [PMID: 31806499 DOI: 10.1016/j.ultrasmedbio.2019.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
282 Zuckerman V, Sokolov E, Swet JH, Ahrens WA, Showlater V, Iannitti DA, Mckillop IH. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells. Oncotarget 2016;7:2951-67. [PMID: 26701886 DOI: 10.18632/oncotarget.6696] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
283 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
284 He Y, Xu R, Peng L, Hu X. Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis. PLoS One 2021;16:e0254829. [PMID: 34324544 DOI: 10.1371/journal.pone.0254829] [Reference Citation Analysis]
285 Yan P, Huang Z, Mou T, Luo Y, Liu Y, Zhou B, Cao Z, Wu Z. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence. BMC Cancer 2021;21:436. [PMID: 33879119 DOI: 10.1186/s12885-021-08173-0] [Reference Citation Analysis]
286 Jiang LH, Hao YL, Zhu JW. Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2019;43:282-91. [PMID: 30385249 DOI: 10.1016/j.clinre.2018.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
287 Zhang DZ, Wei XD, Wang XP. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma. World J Gastroenterol 2015; 21(15): 4635-4643 [PMID: 25914473 DOI: 10.3748/wjg.v21.i15.4635] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
288 Contreras L, Rodríguez-gil A, Muntané J, de la Cruz J. Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells. Cancers 2022;14:1204. [DOI: 10.3390/cancers14051204] [Reference Citation Analysis]
289 Wang M, Gu B, Yao G, Li P, Wang K. Circular RNA Expression Profiles and the Pro-tumorigenic Function of CircRNA_10156 in Hepatitis B Virus-Related Liver Cancer. Int J Med Sci 2020;17:1351-65. [PMID: 32624692 DOI: 10.7150/ijms.45637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
290 Guo XX, Li XP, Zhou P, Li DY, Lyu XT, Chen Y, Lyu YW, Tian K, Yuan DZ, Ran JH, Chen DL, Jiang R, Li J. Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway. Int J Mol Sci 2018;19:E3419. [PMID: 30384473 DOI: 10.3390/ijms19113419] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
291 Min L, Ling W, Hua R, Qi H, Chen S, Wang H, Tang L, Shangguan W. Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Mol Med Rep 2016;13:2518-26. [PMID: 26846752 DOI: 10.3892/mmr.2016.4854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
292 Huang JL, Cao SW, Ou QS, Yang B, Zheng SH, Tang J, Chen J, Hu YW, Zheng L, Wang Q. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol Cancer 2018;17:93. [PMID: 29803224 DOI: 10.1186/s12943-018-0841-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 19.8] [Reference Citation Analysis]
293 Wang Z, Chang Z, Lu M, Shao D, Yue J, Yang D, Zheng X, Li M, He K, Zhang M, Chen L, Dong W. Shape-controlled magnetic mesoporous silica nanoparticles for magnetically-mediated suicide gene therapy of hepatocellular carcinoma. Biomaterials 2018;154:147-57. [DOI: 10.1016/j.biomaterials.2017.10.047] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 16.5] [Reference Citation Analysis]
294 Gao Q, Wang XY, Zhou J, Fan J. Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol. 2015;12:10. [PMID: 25421283 DOI: 10.1038/nrclinonc.2014.122-c1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
295 Chen L, Chu F, Cao Y, Shao J, Wang F. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. Tumor Biol 2015;36:7439-47. [DOI: 10.1007/s13277-015-3430-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
296 Zhu H, Ge K, Lu J, Jia C. Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME. Naunyn-Schmiedeberg's Arch Pharmacol 2019;392:1551-60. [DOI: 10.1007/s00210-019-01701-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
297 Terashima T, Yamashita T, Sunagozaka H, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. Hepatol Res 2018;48:956-66. [PMID: 29845710 DOI: 10.1111/hepr.13196] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
298 Xu D, Wang Y, Wu J, Lin S, Chen Y, Zheng J. Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma. Cancer Cell Int 2021;21:621. [PMID: 34819088 DOI: 10.1186/s12935-021-02326-8] [Reference Citation Analysis]
299 Gu J, Zhang X, Miao R, Ma X, Xiang X, Fu Y, Liu C, Niu W, Qu K. A three-long non-coding RNA-expression-based risk score system can better predict both overall and recurrence-free survival in patients with small hepatocellular carcinoma. Aging (Albany NY). 2018;10:1627-1639. [PMID: 30018179 DOI: 10.18632/aging.101497] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
300 Zhao H, Chen C, Chen X, Zhang D, Li J, Yang C, Ren C, Ren X, Fu X, Li Y, He J, Zhao H. Analysis of CNOT Family Gene Expression, Clinicopathological Features, and Prognosis Value in Hepatocellular Carcinoma. DNA Cell Biol 2020. [PMID: 33085544 DOI: 10.1089/dna.2020.5818] [Reference Citation Analysis]
301 Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O’Neil BH. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Invest New Drugs. 2015;33:505-509. [PMID: 25613083 DOI: 10.1007/s10637-015-0209-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
302 Li B, Huang P, Qiu J, Liao Y, Hong J, Yuan Y. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Med Oncol. 2014;31:230. [PMID: 25218269 DOI: 10.1007/s12032-014-0230-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
303 Yang J, Qiu B, Li X, Zhang H, Liu W. p53-p66shc/miR-21-Sod2 signaling is critical for the inhibitory effect of betulinic acid on hepatocellular carcinoma. Toxicology Letters 2015;238:1-10. [DOI: 10.1016/j.toxlet.2015.07.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
304 Zhang L, Hu J, Hou J, Jiang X, Guo L, Tian L. Radiomics-based model using gadoxetic acid disodium-enhanced MR images: associations with recurrence-free survival of patients with hepatocellular carcinoma treated by surgical resection. Abdom Radiol (NY) 2021;46:3845-54. [PMID: 33733337 DOI: 10.1007/s00261-021-03034-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
305 Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?: A Nomogram-guided Treatment Strategy. Medicine (Baltimore). 2015;94:e1808. [PMID: 26512576 DOI: 10.1097/md.0000000000001808] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
306 Jondal DE, Thompson SM, Butters KA, Knudsen BE, Anderson JL, Roberts LR, Callstrom MR, Woodrum DA. Single-Dose Neoadjuvant AKT Pathway Inhibitor Reduces Growth of Hepatocellular Carcinoma after Laser Thermal Ablation in Small-Animal Model. Radiology 2019;292:752-9. [PMID: 31335281 DOI: 10.1148/radiol.2019190115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
307 Reitano E, de'Angelis N, Bianchi G, Laera L, Spiliopoulos S, Calbi R, Memeo R, Inchingolo R. Current trends and perspectives in interventional radiology for gastrointestinal cancers. World J Radiol 2021; 13(10): 314-326 [PMID: 34786187 DOI: 10.4329/wjr.v13.i10.314] [Reference Citation Analysis]
308 Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu A, Brunner TB. The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol 2018;194:403-13. [DOI: 10.1007/s00066-017-1256-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
309 Yao N, Li YJ, Lei YH, Hu N, Chen WM, Yao Z, Yu M, Liu JS, Ye WC, Zhang DM. A piperazidine derivative of 23-hydroxy betulinic acid induces a mitochondria-derived ROS burst to trigger apoptotic cell death in hepatocellular carcinoma cells. J Exp Clin Cancer Res 2016;35:192. [PMID: 27931237 DOI: 10.1186/s13046-016-0457-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
310 Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, Chen J, Committee G. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol 2016; 22(42): 9279-9287 [PMID: 27895416 DOI: 10.3748/wjg.v22.i42.9279] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 99] [Article Influence: 15.7] [Reference Citation Analysis]
311 Zhao S, Zhang Y, Lu X, Ding H, Han B, Song X, Miao H, Cui X, Wei S, Liu W, Chen S, Wang J. CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway. Int J Biol Sci 2021;17:3608-21. [PMID: 34512169 DOI: 10.7150/ijbs.64003] [Reference Citation Analysis]
312 Zhang M, Pan Y, Dorfman RG, Chen Z, Liu F, Zhou Q, Huang S, Zhang J, Yang D, Liu J. AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition. Oncotarget 2016;7:22285-94. [PMID: 26993777 DOI: 10.18632/oncotarget.8077] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
313 Feng X, Song P, Bie P, Jiang P, Ma K, Li X, Wang S, Wang Z, Tang W, Zheng S. Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery. Med Sci Monit 2016;22:1663-72. [PMID: 27187589 DOI: 10.12659/msm.895483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
314 Leong WQ, Ganpathi IS, Kow AWC, Madhavan K, Chang SKY. Comparative study and systematic review of laparoscopic liver resection for hepatocellular carcinoma. World J Hepatol 2015; 7(27): 2765-2773 [PMID: 26644820 DOI: 10.4254/wjh.v7.i27.2765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
315 Lin T, Gu J, Qu K, Zhang X, Ma X, Miao R, Xiang X, Fu Y, Niu W, She J, Liu C. A new risk score based on twelve hepatocellular carcinoma-specific gene expression can predict the patients' prognosis. Aging (Albany NY) 2018;10:2480-97. [PMID: 30243023 DOI: 10.18632/aging.101563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
316 Gong WF, Zhong JH, Xiang BD, Li LQ. Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy. Mol Clin Oncol 2016;5:3-6. [PMID: 27330754 DOI: 10.3892/mco.2016.871] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
317 Dong Z, Chen Y, Yang C, Zhang M, Chen A, Yang J, Huang Y. STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma. Onco Targets Ther 2019;12:7175-91. [PMID: 31564902 DOI: 10.2147/OTT.S202122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
318 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
319 Wu Y, Zhou Y, Huan L, Xu L, Shen M, Huang S, Liang L. LncRNA MIR22HG inhibits growth, migration and invasion through regulating the miR-10a-5p/NCOR2 axis in hepatocellular carcinoma cells. Cancer Sci 2019;110:973-84. [PMID: 30680848 DOI: 10.1111/cas.13950] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 9.7] [Reference Citation Analysis]
320 Zheng X, Zhang F, Zhao Y, Zhang J, Dawulieti J, Pan Y, Cui L, Sun M, Shao D, Li M, He K, Zhang M, Li J, Chen L. Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics. Theranostics 2018;8:3808-23. [PMID: 30083261 DOI: 10.7150/thno.25255] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
321 Liu B, Teng F, Fu H, Guo WY, Shi XM, Ni ZJ, Gao XG, Ma J, Fu ZR, Ding GS. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation. BMC Gastroenterol 2015;15:138. [PMID: 26472203 DOI: 10.1186/s12876-015-0364-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
322 Guarino M, Caporaso N, Morisco F. Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy. Ann Transl Med 2020;8:1282. [PMID: 33209862 DOI: 10.21037/atm-20-6004] [Reference Citation Analysis]
323 Deng M, Ng SWY, Cheung ST, Chong CCN. Clinical application of Albumin-Bilirubin (ALBI) score: The current status. The Surgeon 2020;18:178-86. [DOI: 10.1016/j.surge.2019.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
324 Yu Q, Xiang L, Yin L, Liu X, Yang D, Zhou J. Loss-of-function of miR-142 by hypermethylation promotes TGF-β-mediated tumour growth and metastasis in hepatocellular carcinoma. Cell Prolif 2017;50. [PMID: 28963738 DOI: 10.1111/cpr.12384] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
325 Jeong JM, Ju C. The Protective Function of PRMT1 in Alcohol-Induced Hepatocellular Carcinoma. Hepatol Commun 2020;4:787-9. [PMID: 32490316 DOI: 10.1002/hep4.1527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 Ye QW, Pang SJ, Yang N, Zhang HB, Fu Y, Lin B, Yang GS. Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study. J Gastrointest Surg 2019;23:1549-58. [PMID: 31197690 DOI: 10.1007/s11605-019-04229-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
327 Chen J, Wang X, Wang X, Li W, Shang C, Chen T, Chen Y. A FITM1-Related Methylation Signature Predicts the Prognosis of Patients With Non-Viral Hepatocellular Carcinoma. Front Genet 2020;11:99. [PMID: 32174969 DOI: 10.3389/fgene.2020.00099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
328 Qu K, Wang Z, Fan H, Li J, Liu J, Li P, Liang Z, An H, Jiang Y, Lin Q, Dong X, Liu P, Liu C. MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma. Cell Death Dis. 2017;8:e2603. [PMID: 28182015 DOI: 10.1038/cddis.2016.352] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
329 Wei S, Liu K, He Q, Gao Y, Shen L. PES1 is regulated by CD44 in liver cancer stem cells via miR-105-5p. FEBS Lett 2019;593:1777-86. [PMID: 31127852 DOI: 10.1002/1873-3468.13459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
330 Shi Y, Wang SY, Yao M, Sai WL, Wu W, Yang JL, Cai Y, Zheng WJ, Yao DF. Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA. World J Gastroenterol. 2015;21:12814-12821. [PMID: 26668505 DOI: 10.3748/wjg.v21.i45.1281426668505] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
331 Yılmaz A, Şimşek M, Hannarici Z, Büyükbayram ME, Bilici M, Tekin SB. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib. Future Oncol 2021;17:4545-59. [PMID: 34431372 DOI: 10.2217/fon-2021-0457] [Reference Citation Analysis]
332 Wu CC. Progress of liver resection for hepatocellular carcinoma in Taiwan. Jpn J Clin Oncol 2017;47:375-80. [PMID: 28159964 DOI: 10.1093/jjco/hyx007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
333 Liu S, Shao R, Bu X, Xu Y, Shi M. Identification of the Pyroptosis-Related Gene Signature for Overall Survival Prediction in Patients With Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:742994. [PMID: 34820372 DOI: 10.3389/fcell.2021.742994] [Reference Citation Analysis]
334 Wei L, Chiu DK, Tsang FH, Law CT, Cheng CL, Au SL, Lee JM, Wong CC, Ng IO, Wong CM. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol 2017;67:758-69. [PMID: 28532996 DOI: 10.1016/j.jhep.2017.05.015] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
335 Zhang SY, Cao N, Chen MK, Zhang LD, Bai YQ, Yang YX. Diagnostic value of plasma HLA-F adjacent transcript 10 mRNA expression in patients with hepatocellular carcinoma or colon cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(36): 5775-5783 [DOI: 10.11569/wcjd.v23.i36.5775] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
336 Huang CY, Wang H, Liao W, Han F, Li YQ, Chen SW, Lao XM. Transforming Growth Factor β is a Poor Prognostic Factor and Inhibits the Favorable Prognostic Value of CD8+ CTL in Human Hepatocellular Carcinoma. J Immunother 2017;40:175-86. [PMID: 28394813 DOI: 10.1097/CJI.0000000000000166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
337 Malek Hosseini SA, Nikeghbalian S, Salahi H, Kazemi K, Shemsaeifar A, Bahador A, Dehghani M, Imanieh MH, Tabrizi R, Lankarani KB. Evolution of Liver Transplantation Program in Shiraz, Iran. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.60745] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
338 Matsushima-nishiwaki R, Toyoda H, Takamatsu R, Yasuda E, Okuda S, Maeda A, Kaneoka Y, Yoshimi N, Kumada T, Kozawa O. Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2017;1863:1629-39. [DOI: 10.1016/j.bbadis.2017.04.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
339 Piracha ZZ, Kwon H, Saeed U, Kim J, Jung J, Chwae YJ, Park S, Shin HJ, Kim K. Sirtuin 2 Isoform 1 Enhances Hepatitis B Virus RNA Transcription and DNA Synthesis through the AKT/GSK-3β/β-Catenin Signaling Pathway. J Virol 2018;92:e00955-18. [PMID: 30111572 DOI: 10.1128/JVI.00955-18] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
340 Zheng Y, Huang Q, Ding Z, Liu T, Xue C, Sang X, Gu J. Genome-wide DNA methylation analysis identifies candidate epigenetic markers and drivers of hepatocellular carcinoma. Brief Bioinform 2018;19:101-8. [PMID: 27760737 DOI: 10.1093/bib/bbw094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
341 Sai W, Wang L, Zheng W, Yang J, Pan L, Cai Y, Qiu L, Zhang H, Wu W, Yao D. Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis. Hepat Mon. 2015;15:e32918. [PMID: 26977166 DOI: 10.5812/hepatmon.32918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
342 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
343 Jaferian S, Soleymaninejad M, Negahdari B, Eatemadi A. Stem cell, biomaterials and growth factors therapy for hepatocellular carcinoma. Biomed Pharmacother 2017;88:1046-53. [PMID: 28192881 DOI: 10.1016/j.biopha.2017.01.154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
344 Liu F, Wang F, Dong X, Xiu P, Sun P, Li Z, Shi X, Zhong J. T7 peptide cytotoxicity in human hepatocellular carcinoma cells is mediated by suppression of autophagy. Int J Mol Med 2019;44:523-34. [PMID: 31173192 DOI: 10.3892/ijmm.2019.4231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
345 Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015;47:505-11. [PMID: 25822088 DOI: 10.1038/ng.3252] [Cited by in Crossref: 792] [Cited by in F6Publishing: 772] [Article Influence: 113.1] [Reference Citation Analysis]
346 Jia Q, Dong Q, Qin L. CCN: core regulatory proteins in the microenvironment that affect the metastasis of hepatocellular carcinoma? Oncotarget 2016;7:1203-14. [PMID: 26497214 DOI: 10.18632/oncotarget.6209] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
347 Gao W, Kim H, Ho M. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PLoS One. 2015;10:e0137664. [PMID: 26332121 DOI: 10.1371/journal.pone.0137664] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
348 Ding Y, Sun Z, Zhang S, Xu Q, Zhou L, Zhou D, Li Y, Han X, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20201479. [PMID: 32697317 DOI: 10.1042/BSR20201479] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
349 Liu X, Huang Y, Jiang C, Ou H, Guo B, Liao H, Li X, Yang D. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma. Dig Liver Dis 2016;48:953-60. [PMID: 27257051 DOI: 10.1016/j.dld.2016.04.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
350 Lu L, Zhang D, Xu Y, Bai G, Lv Y, Liang J. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1. Biomed Pharmacother 2018;104:613-21. [PMID: 29803174 DOI: 10.1016/j.biopha.2018.05.087] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
351 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 12.5] [Reference Citation Analysis]
352 Wang L, Yao M, Pan LH, Qian Q, Yao DF. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14:361-366. [PMID: 26256079 DOI: 10.1016/s1499-3872(15)60396-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
353 Gao J, Dai C, Yu X, Yin XB, Zhou F. Circ-TCF4.85 silencing inhibits cancer progression through microRNA-486-5p-targeted inhibition of ABCF2 in hepatocellular carcinoma. Mol Oncol 2020;14:447-61. [PMID: 31758671 DOI: 10.1002/1878-0261.12603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
354 Liu H, Li B. The functional role of exosome in hepatocellular carcinoma. J Cancer Res Clin Oncol 2018;144:2085-95. [PMID: 30062486 DOI: 10.1007/s00432-018-2712-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
355 Kaufmann S, Thaiss WM, Schulze M, Bitzer M, Lauer U, Nikolaou K, Horger M. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up. Acta Radiol 2018;59:765-72. [PMID: 28927298 DOI: 10.1177/0284185117732805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
356 Liu S, Bu X, Kan A, Luo L, Xu Y, Chen H, Lin X, Lai Z, Wen D, Huang L, Shi M. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett 2021;528:16-30. [PMID: 34958891 DOI: 10.1016/j.canlet.2021.12.026] [Reference Citation Analysis]
357 Jianyong L, Lunan Y, Dajiang L, Wentao W; Liver Surgery Group. Comparison of open liver resection and RFA for the treatment of solitary 3-5-cmhepatocellular carcinoma: a retrospective study. BMC Surg 2019;19:195. [PMID: 31842844 DOI: 10.1186/s12893-019-0663-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
358 Lin CH, Hsieh MJ, Lee HL, Yang SF, Su SC, Lee WJ, Chou YE. Effects of MACC1 polymorphisms on hepatocellular carcinoma development and clinical characteristics. J Cancer 2020;11:1641-7. [PMID: 32047570 DOI: 10.7150/jca.38856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
359 Dugum M, McCullough A. Diagnosis and Management of Alcoholic Liver Disease. J Clin Transl Hepatol 2015;3:109-16. [PMID: 26356792 DOI: 10.14218/JCTH.2015.00008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
360 Berasain C, Avila MA. Regulation of hepatocyte identity and quiescence. Cell Mol Life Sci 2015;72:3831-51. [DOI: 10.1007/s00018-015-1970-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
361 Chen J, Rajasekaran M, Xia H, Zhang X, Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BK, Ooi LL, Hong W, Hui KM. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Gut 2016;65:1522-34. [PMID: 26941395 DOI: 10.1136/gutjnl-2015-310625] [Cited by in Crossref: 127] [Cited by in F6Publishing: 127] [Article Influence: 21.2] [Reference Citation Analysis]
362 Fu C, Xu X, Lu W, Nie L, Yin T, Wu D. Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e17412. [PMID: 31626095 DOI: 10.1097/MD.0000000000017412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
363 Chen Y, Wang Y, Yang Y, Li Y, Wang Y, Wang G, James TD, Xuan X, Zhang H, Liu Y. A molecular-logic gate for COX-2 and NAT based on conformational and structural changes: visualizing the progression of liver disease. Chem Sci 2020;11:6209-16. [PMID: 32953015 DOI: 10.1039/d0sc00574f] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 6.5] [Reference Citation Analysis]
364 Lv J, Liu J, Xiao M, Xu H, Xu C, Zhang X, Tang L, Jiang F, Zhou Y, Zhang Z, Qu L, Lu C. ARP3 promotes tumor metastasis and predicts a poor prognosis in hepatocellular carcinoma. Pathol Res Pract 2018;214:1356-61. [PMID: 30049513 DOI: 10.1016/j.prp.2018.05.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
365 Furukawa K, Shiba H, Horiuchi T, Shirai Y, Haruki K, Fujiwara Y, Sakamoto T, Gocho T, Yanaga K. Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona Clinic Liver Cancer classification. J Hepatobiliary Pancreat Sci. 2017;24:199-205. [PMID: 28160422 DOI: 10.1002/jhbp.436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
366 El Sherbiny W, AbdelRahman A, Diasty M, Shaltout SW. Changes in Doppler parameters of portal pressure after interventional management of hepatocellular carcinoma. Abdom Radiol (NY) 2016;41:1532-8. [PMID: 26971951 DOI: 10.1007/s00261-016-0704-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
367 Lu WL, Yang T, Song QJ, Fang ZQ, Pan ZQ, Liang C, Jia DW, Peng PK. Akebia trifoliata (Thunb.) Koidz Seed Extract inhibits human hepatocellular carcinoma cell migration and invasion in vitro. J Ethnopharmacol 2019;234:204-15. [PMID: 30528882 DOI: 10.1016/j.jep.2018.11.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
368 Chen B, Zhou S, Zhan Y, Ke J, Wang K, Liang Q, Hou Y, Zhu P, Ao W, Wei X, Xiao J. Dioscin Inhibits the Invasion and Migration of Hepatocellular Carcinoma HepG2 Cells by Reversing TGF-β1-Induced Epithelial-Mesenchymal Transition. Molecules 2019;24:E2222. [PMID: 31197076 DOI: 10.3390/molecules24122222] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
369 Liu J, Kuang S, Zheng Y, Liu M, Wang L. Prognostic and predictive significance of the tumor microenvironment in hepatocellular carcinoma. Cancer Biomark 2021;32:99-110. [PMID: 34092607 DOI: 10.3233/CBM-203003] [Reference Citation Analysis]
370 Wang D, Zhu Y, Tang J, Lian Q, Luo G, Wen W, Zhang MQ, Wang H, Chen L, Gu J. Integrative molecular analysis of metastatic hepatocellular carcinoma. BMC Med Genomics 2019;12:164. [PMID: 31722693 DOI: 10.1186/s12920-019-0586-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
371 Ramaswami R, Pinato DJ, Kubota K, Ishizuka M, Arizumi T, Kudo M, Jang JW, Kim YW, Pirisi M, Allara E, Sharma R. Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. Med Oncol 2016;33:114. [PMID: 27601241 DOI: 10.1007/s12032-016-0827-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
372 Li XD, Wang Z, Wang XR, Shao D, Zhang X, Li L, Ge MF, Chang ZM, Dong WF. Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition. Int J Nanomedicine 2019;14:3967-82. [PMID: 31239666 DOI: 10.2147/IJN.S206044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
373 Shi Y, Wang SY, Yao M, Sai WL, Wu W, Yang JL, Cai Y, Zheng WJ, Yao DF. Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA. World J Gastroenterol 2015; 21(45): 12814-12821 [PMID: 26668505 DOI: 10.3748/wjg.v21.i45.12814] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
374 Lu XJ, Dong J, Ji LJ, Luo JH, Cao HM, Xiao LX, Zhou J, Ling CQ. Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion. Gut 2016;65:715-6. [PMID: 26268743 DOI: 10.1136/gutjnl-2015-310292] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
375 Chen HA, Li CC, Lin YJ, Wang TF, Chen MC, Su YH, Yeh YL, Padma VV, Liao PH, Huang CY. Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells. Aging (Albany NY) 2021;13:12046-57. [PMID: 33901009 DOI: 10.18632/aging.202908] [Reference Citation Analysis]
376 Bai L, Ren Y, Cui T. Overexpression of CDCA5, KIF4A, TPX2, and FOXM1 Coregulated Cell Cycle and Promoted Hepatocellular Carcinoma Development. J Comput Biol 2020;27:965-74. [PMID: 31593490 DOI: 10.1089/cmb.2019.0254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
377 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut 2018;67:380-8. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 23.0] [Reference Citation Analysis]
378 Wong VW, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol. 2015;63:722-732. [PMID: 26026875 DOI: 10.1016/j.jhep.2015.05.019] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
379 Wang J, Sun J, Zhang N, Yang R, Li H, Zhang Y, Chen K, Kong D. PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway. Life Sci 2019;219:182-9. [PMID: 30630006 DOI: 10.1016/j.lfs.2018.12.054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
380 Zhang N, Ma D, Wang L, Zhu X, Pan Q, Zhao Y, Zhu W, Zhou J, Wang L, Chai Z, Ao J, Sun H, Tang Z. Insufficient Radiofrequency Ablation Treated Hepatocellular Carcinoma Cells Promote Metastasis by Up-Regulation ITGB3. J Cancer 2017;8:3742-54. [PMID: 29151962 DOI: 10.7150/jca.20816] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
381 Yang N, Wang T, Li Q, Han F, Wang Z, Zhu R, Zhou J. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α. J Cell Physiol 2021;236:3863-80. [PMID: 33305825 DOI: 10.1002/jcp.30128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
382 Ding Y, Xie Q, Liu W, Pan Z, Fan X, Chen X, Li M, Zhao W, Li D, Zheng Q. Neochamaejasmin A Induces Mitochondrial-Mediated Apoptosis in Human Hepatoma Cells via ROS-Dependent Activation of the ERK1/2/JNK Signaling Pathway. Oxid Med Cell Longev 2020;2020:3237150. [PMID: 32411325 DOI: 10.1155/2020/3237150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
383 Zhong JH, Wu FX, Li H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol 2014;35:8355-8. [PMID: 25195949 DOI: 10.1007/s13277-014-2571-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
384 Xiang X, Zhong JH, Wang YY, You XM, Ma L, Xiang BD, Li LQ. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. Clin Transl Oncol 2017;19:891-7. [PMID: 28160206 DOI: 10.1007/s12094-017-1621-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
385 Gao J, Li E, Liu W, Yang Q, Xie C, Ai J, Zhou F, Liao W, Wu L. Circular RNA MYLK Promotes Hepatocellular Carcinoma Progression Through the miR29a/KMT5C Signaling Pathway. Onco Targets Ther 2020;13:8615-27. [PMID: 32904604 DOI: 10.2147/OTT.S258715] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
386 Chen Y, Chiu W, Chang C, Wu P, Tu T, Lin H, Chang H. Chemo-photothermal effects of doxorubicin/silica–carbon hollow spheres on liver cancer. RSC Adv 2018;8:36775-84. [DOI: 10.1039/c8ra08538b] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
387 Wakabayashi T, Ouhmich F, Gonzalez-Cabrera C, Felli E, Saviano A, Agnus V, Savadjiev P, Baumert TF, Pessaux P, Marescaux J, Gallix B. Radiomics in hepatocellular carcinoma: a quantitative review. Hepatol Int. 2019;13:546-559. [PMID: 31473947 DOI: 10.1007/s12072-019-09973-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
388 Xu J, Yan B, Zhang L, Zhou L, Zhang J, Yu W, Dong X, Yao L, Shan L. Theabrownin Induces Apoptosis and Tumor Inhibition of Hepatocellular Carcinoma Huh7 Cells Through ASK1-JNK-c-Jun Pathway. Onco Targets Ther 2020;13:8977-87. [PMID: 32982289 DOI: 10.2147/OTT.S254693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
389 Huang C, Li K, Huang R, Zhu J, Yang J. RNF185-AS1 promotes hepatocellular carcinoma progression through targeting miR-221-5p/integrin β5 axis. Life Sci 2021;267:118928. [PMID: 33358902 DOI: 10.1016/j.lfs.2020.118928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
390 Briggs G, Wallace D, Flasche S, Walker K, Cowling T, Heaton N, van der Meulen J, Samyn M, Joshi D. Inferior outcomes in young adults undergoing liver transplantation - a UK and Ireland cohort study. Transpl Int 2021. [PMID: 34486751 DOI: 10.1111/tri.14033] [Reference Citation Analysis]
391 Cai XR, Li X, Lin JX, Wang TT, Dong M, Chen ZH, Jia CC, Hong YF, Lin Q, Wu XY. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review. Oncotarget 2017;8:31318-28. [PMID: 28412743 DOI: 10.18632/oncotarget.15454] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
392 Jia Y, Li S, Zhang M, Zhang Z, Wang C, Zhang C, Yang W, Peng L, Xu Z. Circ_LDLR Knockdown Suppresses Progression of Hepatocellular Carcinoma via Modulating miR-7/RNF38 Axis. Cancer Manag Res 2021;13:337-49. [PMID: 33469375 DOI: 10.2147/CMAR.S275003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Kuo FY, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH. Microscopic portal vein invasion is a powerful predictor of prognosis in patients with hepatocellular carcinoma who have undergone liver resection. J Surg Oncol 2021;123:222-35. [PMID: 33084068 DOI: 10.1002/jso.26260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
394 Li JD, Xu XF, Han J, Wu H, Xing H, Li C, Yu JJ, Zhou YH, Gu WM, Wang H, Chen TH, Zeng YY, Lau WY, Wu MC, Shen F, Yang T. Preoperative prealbumin level as an independent predictor of long-term prognosis after liver resection for hepatocellular carcinoma: a multi-institutional study. HPB (Oxford). 2019;21:157-166. [PMID: 30082212 DOI: 10.1016/j.hpb.2018.06.1803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
395 Hu C, Jiang D, Wu M, Wang J, Zhang R. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of VEGFR2-targeted CD-TK-loaded cationic nanobubbles in the treatment of bladder cancer. J Cancer Res Clin Oncol 2020;146:1415-26. [DOI: 10.1007/s00432-020-03160-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
396 Sherman M, Bruix J. Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice. Hepatology 2015;61:433-6. [PMID: 25308482 DOI: 10.1002/hep.27563] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
397 Wallace D, Walker K, Charman S, Suddle A, Gimson A, Rowe I, Callaghan C, Cowling T, Heaton N, van der Meulen J. Assessing the Impact of Suboptimal Donor Characteristics on Mortality After Liver Transplantation: A Time-dependent Analysis Comparing HCC With Non-HCC Patients. Transplantation 2019;103:e89-98. [DOI: 10.1097/tp.0000000000002559] [Cited by in Crossref: 11] [Article Influence: 3.7] [Reference Citation Analysis]
398 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7(4): 673-687 [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
399 Lei J, Zhong J, Hao J, Liu Z, Zhang P, Wu L, Yan L, Zhu J, Zeng Y, Li B, Wen T, Wang W. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. Oncotarget 2016;7:42598-607. [PMID: 26981887 DOI: 10.18632/oncotarget.3799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
400 García-Irigoyen O, Latasa MU, Carotti S, Uriarte I, Elizalde M, Urtasun R, Vespasiani-Gentilucci U, Morini S, Benito P, Ladero JM, Rodriguez JA, Prieto J, Orbe J, Páramo JA, Fernández-Barrena MG, Berasain C, Avila MA. Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis. Hepatology 2015;62:166-78. [PMID: 25808184 DOI: 10.1002/hep.27798] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
401 Lin GH, Shih YL. Paraplegia following transarterial chemoembolisation for hepatocellular carcinoma: a case report. Acta Chir Belg 2021;121:437-40. [PMID: 32031042 DOI: 10.1080/00015458.2020.1726097] [Reference Citation Analysis]
402 Yuan J, Yin X, Tang B, Ma H, Zhang L, Li L, Chen R, Xie X, Ren Z. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. Biomed Res Int 2019;2019:2141859. [PMID: 31467872 DOI: 10.1155/2019/2141859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
403 Liao S, Chen H, Liu M, Gan L, Li C, Zhang W, Lv L, Mei Z. Aquaporin 9 inhibits growth and metastasis of hepatocellular carcinoma cells via Wnt/β-catenin pathway. Aging (Albany NY) 2020;12:1527-44. [PMID: 31969493 DOI: 10.18632/aging.102698] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
404 Yan Y, Huang P, Mao K, He C, Xu Q, Zhang M, Liu H, Zhou Z, Zhou Q, Zhou Q, Ou B, Liu Q, Lin J, Chen R, Wang J, Zhang J, Xiao Z. Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression. Oncogene 2021;40:28-45. [PMID: 33051595 DOI: 10.1038/s41388-020-01498-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
405 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 10.6] [Reference Citation Analysis]
406 Tang B, Tian Y, Liao Y, Li Z, Yu S, Su H, Zhong F, Yuan G, Wang Y, Yu H, Tomlinson S, Qiu X, He S. CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma. Cell Death Dis 2019;10:52. [PMID: 30718464 DOI: 10.1038/s41419-018-1288-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
407 Jung JW, Yoon SM, Kim S, Jeon YH, Yoon BH, Yang SG, Kim MK, Choe S, Kuo MM. Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population. Oncotarget 2016;7:73754-68. [PMID: 27650540 DOI: 10.18632/oncotarget.12062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
408 Yassin NYS, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomed Pharmacother 2021;145:112409. [PMID: 34781148 DOI: 10.1016/j.biopha.2021.112409] [Reference Citation Analysis]
409 Lv Y, Wei W, Huang Z, Chen Z, Fang Y, Pan L, Han X, Xu Z. Long non-coding RNA expression profile can predict early recurrence in hepatocellular carcinoma after curative resection: LncRNA expression profile to predict HCC recurrence. Hepatol Res 2018;48:1140-8. [DOI: 10.1111/hepr.13220] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
410 Ikenaga H, Uchida-Kobayashi S, Tamori A, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Enomoto M, Kawada N. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat 2021. [PMID: 34695288 DOI: 10.1111/jvh.13627] [Reference Citation Analysis]
411 Guarino M, Stroffolini T, Lombardo FL, Loperto I, Auriemma F, Gentile I, Caporaso N, Morisco F. Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. J Med Virol 2015;87:1368-76. [PMID: 25802203 DOI: 10.1002/jmv.24187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
412 Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis. J Cancer 2015;6:394-402. [PMID: 25767611 DOI: 10.7150/jca.11212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
413 Weng X, Zeng L, Yan F, He M, Wu X, Zheng D. Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib. Onco Targets Ther 2019;12:5025-36. [PMID: 31388306 DOI: 10.2147/OTT.S196607] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
414 Shi W, Huang W, Chen Y, Zhang S, Xu P, Gu X, Fan H, Xu J, Chen Y, Ni R, Lu C, Zhang X. Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma. Tumour Biol 2016;37:10447-57. [PMID: 26846109 DOI: 10.1007/s13277-015-4556-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
415 Kang H, Heo S, Shin JJ, Ji E, Tak H, Ahn S, Lee KJ, Lee EK, Kim W. A miR‐194/PTBP1/CCND3 axis regulates tumor growth in human hepatocellular carcinoma. J Pathol 2019;249:395-408. [DOI: 10.1002/path.5325] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
416 Chu HH, Kim JH, Yoon HK, Ko HK, Gwon DI, Kim PN, Sung KB, Ko GY, Kim SY, Park SH. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis. J Vasc Interv Radiol. 2019;30:1533-1543. [PMID: 31471190 DOI: 10.1016/j.jvir.2019.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
417 Faria SC, Sagebiel T, Patnana M, Cox V, Viswanathan C, Lall C, Qayyum A, Bhosale PR. Tumor markers: myths and facts unfolded. Abdom Radiol (NY) 2019;44:1575-600. [PMID: 30498924 DOI: 10.1007/s00261-018-1845-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
418 Chen W, Ma T, Zhang J, Zhang X, Chen W, Shen Y, Bai X, Liang T. A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. HPB 2020;22:795-808. [DOI: 10.1016/j.hpb.2019.12.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
419 Coilly A, Roche B, Duclos-Vallée JC, Samuel D. Optimum timing of treatment for hepatitis C infection relative to liver transplantation. Lancet Gastroenterol Hepatol 2016;1:165-72. [PMID: 28404073 DOI: 10.1016/S2468-1253(16)30008-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
420 Perkons NR, Stein EJ, Nwaezeapu C, Wildenberg JC, Saleh K, Itkin-Ofer R, Ackerman D, Soulen MC, Hunt SJ, Nadolski GJ, Gade TP. Electrolytic ablation enables cancer cell targeting through pH modulation. Commun Biol 2018;1:48. [PMID: 30271931 DOI: 10.1038/s42003-018-0047-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
421 Bai C, Hu P, Liu N, Feng G, Liu D, Chen Y, Ma M, Gu N, Zhang Y. Synthesis of Ultrasmall Fe 3 O 4 Nanoparticles as T1T2 Dual-Modal Magnetic Resonance Imaging Contrast Agents in Rabbit Hepatic Tumors. ACS Appl Nano Mater 2020;3:3585-95. [DOI: 10.1021/acsanm.0c00306] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
422 Iida H, Kaibori M, Hirokawa F, Inoue Y, Ueno M, Matsui K, Ishizaki M, Tanaka S, Takemura S, Nomi T, Hokutou D, Noda T, Eguchi H, Nakai T, Maehira H, Mori H, Tani M, Kubo S. New Hepatic Resection Criteria for Intermediate-Stage Hepatocellular Carcinoma Can Improve Long-Term Survival: A Retrospective, Multicenter Collaborative Study. Asian Pac J Cancer Prev 2020;21:2903-11. [PMID: 33112547 DOI: 10.31557/APJCP.2020.21.10.2903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ, Pan K, Huang LX, He J, Zhao JJ, Jiang SS, Zhang XF, Zhang HX, Zhou ZQ, Weng de S, Xia JC. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget 2016;7:16248-61. [PMID: 26919247 DOI: 10.18632/oncotarget.7637] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
424 Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH; C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755-1764. [PMID: 27634134 DOI: 10.1111/liv.13253] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
425 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
426 Yu S, Chen J, Quan M, Li L, Li Y, Gao Y. CD63 negatively regulates hepatocellular carcinoma development through suppression of inflammatory cytokine-induced STAT3 activation. J Cell Mol Med 2021;25:1024-34. [PMID: 33277798 DOI: 10.1111/jcmm.16167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
427 Boulin M, Delhom E, Pierredon-foulongne M, Cercueil J, Guiu B. Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day. Diagnostic and Interventional Imaging 2015;96:607-15. [DOI: 10.1016/j.diii.2015.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
428 Fang Z, He L, Jia H, Huang Q, Chen D, Zhang Z. The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer. Iran J Basic Med Sci 2017;20:187-92. [PMID: 28293396 DOI: 10.22038/ijbms.2017.8246] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
429 Yoon JH, Lee WJ, Kim SM, Kim KT, Cho SB, Kim HJ, Ko YS, Kook HY, Jun CH, Choi SK, Kim BS, Cho SY, You HS, Lee Y, Son S. Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Sci Rep 2021;11:12984. [PMID: 34155324 DOI: 10.1038/s41598-021-92503-6] [Reference Citation Analysis]
430 Rinaldi L, Nascimbeni F, Giordano M, Masetti C, Guerrera B, Amelia A, Fascione MC, Ballestri S, Romagnoli D, Zampino R, Nevola R, Baldelli E, Iuliano N, Rosato V, Lonardo A, Adinolfi LE. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol 2017; 23(8): 1458-1468 [PMID: 28293093 DOI: 10.3748/wjg.v23.i8.1458] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
431 Ou Q, Ma N, Yu Z, Wang R, Hou Y, Wang Z, Chen F, Li W, Bi J, Ma J, Zhang L, Su Q, Huang X. Nudix hydrolase 1 is a prognostic biomarker in hepatocellular carcinoma. Aging (Albany NY) 2020;12:7363-79. [PMID: 32341205 DOI: 10.18632/aging.103083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
432 Kou P, Zhang C, Lin J, Wang H. Circular RNA hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinoma. Oncol Lett 2019;17:2091-8. [PMID: 30675276 DOI: 10.3892/ol.2018.9863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
433 Lan YT, Fan XP, Fan YC, Zhao J, Wang K. Change in the Treg/Th17 cell imbalance in hepatocellular carcinoma patients and its clinical value. Medicine (Baltimore) 2017;96:e7704. [PMID: 28796055 DOI: 10.1097/MD.0000000000007704] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
434 Jiang J, Huang Z, Chen X, Luo R, Cai H, Wang H, Zhang H, Sun T, Zhang Y. Trifluoperazine Activates FOXO1-Related Signals to Inhibit Tumor Growth in Hepatocellular Carcinoma. DNA Cell Biol 2017;36:813-21. [PMID: 28876084 DOI: 10.1089/dna.2017.3790] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
435 Sueoka S, Kanda M, Sugimoto H, Shimizu D, Nomoto S, Oya H, Takami H, Ezaka K, Hashimoto R, Tanaka Y, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Fujiwara M, Kodera Y. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. Ann Surg Oncol 2015;22:1453-60. [DOI: 10.1245/s10434-015-4524-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
436 Zhou Y, Wang B, Wu J, Zhang C, Zhou Y, Yang X, Zhou J, Guo W, Fan J. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. BMC Cancer 2016;16:506. [PMID: 27439521 DOI: 10.1186/s12885-016-2526-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
437 Cao J, Hou P, Chen J, Wang P, Wang W, Liu W, Liu C, He X. The overexpression and prognostic role of DCAF13 in hepatocellular carcinoma. Tumour Biol 2017;39:1010428317705753. [PMID: 28631558 DOI: 10.1177/1010428317705753] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
438 Huang L, Yang Q, Chen H, Wang Z, Liu Q, Ai S. Tollip promotes hepatocellular carcinoma progression via PI3K/AKT pathway. Open Medicine 2022;17:626-37. [DOI: 10.1515/med-2022-0453] [Reference Citation Analysis]
439 Azam F, Sheikh N, Ali G, Tayyeb A. Fagonia indica Repairs Hepatic Damage through Expression Regulation of Toll-Like Receptors in a Liver Injury Model. J Immunol Res 2018;2018:7967135. [PMID: 30057922 DOI: 10.1155/2018/7967135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
440 Jayant K, Sodergren MH, Reccia I, Kusano T, Zacharoulis D, Spalding D, Pai M, Jiao LR, Huang KW. A Systematic Review and Meta-Analysis Comparing Liver Resection with the Rf-Based Device Habib™-4X with the Clamp-Crush Technique. Cancers (Basel) 2018;10:E428. [PMID: 30413094 DOI: 10.3390/cancers10110428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
441 Wei PL, Hung CS, Lu HH, Batzorig U, Huang CY, Chang YJ. Areca nut extract (ANE) inhibits the progression of hepatocellular carcinoma cells via activation of ROS production and activation of autophagy. Int J Med Sci 2021;18:3452-62. [PMID: 34522171 DOI: 10.7150/ijms.61570] [Reference Citation Analysis]
442 Xu X, Liu Z, Wang J, Xie H, Li J, Cao J, Zhou L, Zheng S. Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma. Oncotarget 2016;7:13730-41. [PMID: 26883192 DOI: 10.18632/oncotarget.7316] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
443 Lin Z, Cai Y, Chen R, Chen B, Zhao L, Xu S, Wang X, Song M, Wu J, Wang Y, Zhou M, Shi K. A microRNA expression profile for vascular invasion can predict overall survival in hepatocellular carcinoma. Clinica Chimica Acta 2017;469:171-9. [DOI: 10.1016/j.cca.2017.03.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
444 Jin Y, Li Q, Qiu J, Zhao X, Zheng C, Lv S, Bai Y, Shan Y, Ye LC. Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis. Tumour Biol 2016;37:14193-203. [PMID: 27553024 DOI: 10.1007/s13277-016-5247-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
445 Wang C, Yao B, Xu M, Zheng X. RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC. Tumor Biol 2016;37:15305-13. [DOI: 10.1007/s13277-016-5342-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
446 Niu Y, Lin Z, Wan A, Sun L, Yan S, Liang H, Zhan S, Chen D, Bu X, Liu P, Chen C, He W, Lu X, Wan G. Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia. Hepatology 2021;74:1461-79. [PMID: 33813748 DOI: 10.1002/hep.31846] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
447 Li L, Cao Y, Fan Y, Li R. Gene signature to predict prognostic survival of hepatocellular carcinoma. Open Medicine 2021;17:135-50. [DOI: 10.1515/med-2021-0405] [Reference Citation Analysis]
448 Zheng X, Zhang F, Shao D, Zhang Z, Cui L, Zhang J, Dawulieti J, Meng Z, Zhang M, Chen L. Gram-scale production of carrier-free fluorescent berberine microrods for selective liver cancer therapy: Carrier-free fluorescent berberine microrods. BioFactors 2018;44:496-502. [DOI: 10.1002/biof.1450] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
449 Lin B, He H, Zhang Q, Zhang J, Xu L, Zhou L, Zheng S, Wu L. Long non-coding RNA00844 inhibits MAPK signaling to suppress the progression of hepatocellular carcinoma by targeting AZGP1. Ann Transl Med 2020;8:1365. [PMID: 33313110 DOI: 10.21037/atm-20-3848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
450 Chen S, Jin H, Dai Z, Wei M, Xiao H, Su T, Li B, Liu X, Wang Y, Li J, Shen S, Zhou Q, Peng B, Peng Z, Peng S. Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma. Cancer Med 2019;8:1530-9. [PMID: 30864247 DOI: 10.1002/cam4.2038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
451 Ren B, Zou G, Xu F, Huang Y, Xu G, He J, Li Y, Zhu H, Yu P. Serum levels of anti-sperm-associated antigen 9 antibody are elevated in patients with hepatocellular carcinoma. Oncol Lett. 2017;14:7608-7614. [PMID: 29344208 DOI: 10.3892/ol.2017.7152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
452 Hu T, Li J, Zhang C, Lv X, Li S, He S, Yan H, Tan Y, Lei M, Wen M, Zuo J. The potential value of microRNA-4463 in the prognosis evaluation in hepatocellular carcinoma. Genes Dis 2017;4:116-22. [PMID: 30258914 DOI: 10.1016/j.gendis.2017.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
453 Feng R, Li J, Xuan W, Liu H, Cheng D, Wang G. An Autophagy-Related Gene-Based Prognostic Risk Signature for Hepatocellular Carcinoma: Construction and Validation. Comput Math Methods Med 2021;2021:5770228. [PMID: 34691238 DOI: 10.1155/2021/5770228] [Reference Citation Analysis]
454 Liu Z, Guo H, Gao F, Shan Q, Li J, Xie H, Zhou L, Xu X, Zheng S. Fibrinogen and D-dimer levels elevate in advanced hepatocellular carcinoma: High pretreatment fibrinogen levels predict poor outcomes. Hepatol Res. 2017;47:1108-1117. [PMID: 27914119 DOI: 10.1111/hepr.12848] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
455 Chen ZH, Hong YF, Lin J, Li X, Wu DH, Wen JY, Chen J, Ruan DY, Lin Q, Dong M, Wei L, Wang TT, Lin ZX, Ma XK, Wu XY, Xu R. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett 2017;14:705-14. [PMID: 28693224 DOI: 10.3892/ol.2017.6222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
456 Xing H, Wang Z, Shao D, Chang Z, Ge M, Li L, Wu M, Yan Z, Dong W. Janus nanocarriers for magnetically targeted and hyperthermia-enhanced curcumin therapy of liver cancer. RSC Adv 2018;8:30448-54. [DOI: 10.1039/c8ra05694c] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
457 Li X, Chen ZH, Ma XK, Chen J, Wu DH, Lin Q, Dong M, Wei L, Wang TT, Ruan DY. Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol. 2014;35:11057-11063. [PMID: 25095975 DOI: 10.1007/s13277-014-2360-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
458 Dou W, Yang M, Su Y, Xie R. Dysregulation of miR-3607 predicts prognosis of hepatocellular carcinoma and regulates tumor cell proliferation, migration and invasion. Diagn Pathol 2020;15:54. [PMID: 32404179 DOI: 10.1186/s13000-020-00973-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
459 Crescenzi M, Tessari A, Biasiolo A, Padoan A, Gallotta A, Fassina G, Panciatichi C, Rossetto O, Pontisso P, Basso D, Plebani M. Analytical validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. Anal Methods 2015;7:629-37. [DOI: 10.1039/c4ay02495h] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
460 Feng YX, Li W, Wen XD, Zhang N, Liu WH, Yang ZY. Sinusoidal Endothelial Cell Progenitor Cells Promote Tumour Progression in Patients with Hepatocellular Carcinoma. Stem Cells Int 2020;2020:8819523. [PMID: 33312206 DOI: 10.1155/2020/8819523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
461 Li H, Han G, Li X, Li B, Wu B, Jin H, Wu L, Wang W. MAPK-RAP1A Signaling Enriched in Hepatocellular Carcinoma Is Associated With Favorable Tumor-Infiltrating Immune Cells and Clinical Prognosis. Front Oncol 2021;11:649980. [PMID: 34178637 DOI: 10.3389/fonc.2021.649980] [Reference Citation Analysis]
462 Li T, Xue Y, Wang G, Gu T, Li Y, Zhu YY, Chen L. Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma. J Cancer 2016;7:1317-27. [PMID: 27390607 DOI: 10.7150/jca.15157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
463 Chang JH, Lin CH, Shibu MA, Chou YC, Liu JY, Chou YH, Shen CY, Yeh YL, Viswanadha VP, Huang CY. Cryptotanshinone (Dsh-003) from Salvia miltiorrhiza Bunge inhibits prostaglandin E2-induced survival and invasion effects in HA22T hepatocellular carcinoma cells. Environ Toxicol 2018;33:1254-60. [PMID: 30208247 DOI: 10.1002/tox.22633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
464 Gao F, Zhu HK, Zhu YB, Shan QN, Ling Q, Wei XY, Xie HY, Zhou L, Xu X, Zheng SS. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern. Hepatobiliary Pancreat Dis Int 2016;15:371-7. [PMID: 27498576 DOI: 10.1016/s1499-3872(16)60095-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
465 Wang R, Liu Y, Mi X, Chen Q, Jiang P, Hou J, Lin Y, Li S, Ji B, Fang Y. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction. Arch Biochem Biophys 2020;689:108415. [PMID: 32562663 DOI: 10.1016/j.abb.2020.108415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
466 Song ZB, Yu Y, Zhang GP, Li SQ. Genomic Instability of Mutation-Derived Gene Prognostic Signatures for Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:728574. [PMID: 34676211 DOI: 10.3389/fcell.2021.728574] [Reference Citation Analysis]
467 Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J Clin Oncol 2017; 8(3): 203-213 [PMID: 28638790 DOI: 10.5306/wjco.v8.i3.203] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
468 Wan J, Liu H, Ming L. Lysine crotonylation is involved in hepatocellular carcinoma progression. Biomed Pharmacother 2019;111:976-82. [PMID: 30841477 DOI: 10.1016/j.biopha.2018.12.148] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
469 Wang Y, Wang Z, Jia F, Xu Q, Shu Z, Deng J, Li A, Yu M, Yu Z. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment. Bioactive Materials 2022;17:147-61. [DOI: 10.1016/j.bioactmat.2022.01.003] [Reference Citation Analysis]
470 Zhang X, Hu B, Sun YF, Huang XW, Cheng JW, Huang A, Zeng HY, Qiu SJ, Cao Y, Fan J, Zhou J, Yang XR. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med 2021;11:e335. [PMID: 33634982 DOI: 10.1002/ctm2.335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
471 He B, Li T, Guan L, Liu FE, Chen XM, Zhao J, Lin S, Liu ZZ, Zhang HQ. CTNNA3 is a tumor suppressor in hepatocellular carcinomas and is inhibited by miR-425. Oncotarget 2016;7:8078-89. [PMID: 26882563 DOI: 10.18632/oncotarget.6978] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
472 Liu F, Liu W, Sanin DE, Jia G, Tian M, Wang H, Zhu B, Lu Y, Qiao T, Wang X, Shi Y, Wu D. Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma. Oncoimmunology 2020;9:1746573. [PMID: 32426177 DOI: 10.1080/2162402X.2020.1746573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
473 Sun S, Gao J, Zhou S, Li Y, Wang Y, Jin L, Li J, Liu B, Zhang B, Han S, Ding H, Li X. A novel circular RNA circ-LRIG3 facilitates the malignant progression of hepatocellular carcinoma by modulating the EZH2/STAT3 signaling. J Exp Clin Cancer Res 2020;39:252. [PMID: 33222697 DOI: 10.1186/s13046-020-01779-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
474 Gu X, Li H, Sha L, Zhao W. A prognostic model composed of four long noncoding RNAs predicts the overall survival of Asian patients with hepatocellular carcinoma. Cancer Med 2020;9:5719-30. [PMID: 32946170 DOI: 10.1002/cam4.3275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
475 Zhu Y, Dong M, Yang J, Zhang J. Evaluation of Iodine-125 Interstitial Brachytherapy Using Micro-Positron Emission Tomography/Computed Tomography with 18F-Fluorodeoxyglucose in Hepatocellular Carcinoma HepG2 Xenografts. Med Sci Monit 2019;25:371-80. [PMID: 30636171 DOI: 10.12659/MSM.912590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
476 Terashima T, Honda M, Toyama T, Shimakami T, Shimizu R, Takatori H, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S. IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. J Gastroenterol Hepatol 2020;35:1813-20. [PMID: 32180251 DOI: 10.1111/jgh.15035] [Reference Citation Analysis]
477 Scudellari M. Drug development: try and try again. Nature 2014;516:S4-6. [PMID: 25470198 DOI: 10.1038/516S4a] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
478 He S, Hu XW, Wang D, Han LF, Zhang DC, Wei C. Accuracy of microRNAs for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2016; Mar 23. [Epub ahead of print]. [PMID: 27016891 DOI: 10.1016/j.clinre.2016.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
479 Xin F, Wu M, Cai Z, Zhang X, Wei Z, Liu X, Liu J. Tumor Microenvironment Triggered Cascade-Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma. Adv Healthc Mater 2021;10:e2002036. [PMID: 33644987 DOI: 10.1002/adhm.202002036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
480 Nishiyama M, Tsunedomi R, Yoshimura K, Hashimoto N, Matsukuma S, Ogihara H, Kanekiyo S, Iida M, Sakamoto K, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Ueno T, Hamamoto Y, Hazama S, Nagano H. Metastatic ability and the epithelial-mesenchymal transition in induced cancer stem-like hepatoma cells. Cancer Sci 2018;109:1101-9. [PMID: 29417690 DOI: 10.1111/cas.13527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
481 Yan X, Qiu Y. Impact of current staging systems on treatment strategy for HBV-related hepatocellular carcinoma. Cancer Lett 2016;379:220-4. [PMID: 26282785 DOI: 10.1016/j.canlet.2015.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
482 Zheng JF, He S, Zeng Z, Gu X, Cai L, Qi G. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy. Mol Ther 2019;27:1784-95. [PMID: 31337603 DOI: 10.1016/j.ymthe.2019.06.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
483 Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG, Sun DX. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int 2015;15:45. [PMID: 25908926 DOI: 10.1186/s12935-015-0195-z] [Cited by in Crossref: 66] [Cited by in F6Publishing: 76] [Article Influence: 9.4] [Reference Citation Analysis]
484 Xu XF, Xing H, Han J, Li ZL, Lau WY, Zhou YH, Gu WM, Wang H, Chen TH, Zeng YY, Li C, Wu MC, Shen F, Yang T. Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China. JAMA Surg. 2019;154:209-217. [PMID: 30422241 DOI: 10.1001/jamasurg.2018.4334] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 28.3] [Reference Citation Analysis]
485 Deng Y, Zhang F, Sun ZG, Wang S. Development and Validation of a Prognostic Signature Associated With Tumor Microenvironment Based on Autophagy-Related lncRNA Analysis in Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:762570. [PMID: 34970559 DOI: 10.3389/fmed.2021.762570] [Reference Citation Analysis]
486 Zhang Y, Liu Y, Duan J, Yan H, Zhang J, Zhang H, Fan Q, Luo F, Yan G, Qiao K, Liu J. Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21(Waf/Cip1) stabilization by activating the ERK1/2-MAPK pathway. Hepatology 2016;63:880-97. [PMID: 26659654 DOI: 10.1002/hep.28395] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
487 Guo W, Li H, Liu H, Ma X, Yang S, Wang Z. DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway. Oncol Rep 2019;42:1075-89. [PMID: 31322256 DOI: 10.3892/or.2019.7221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
488 Zhou X, Liu C, Zeng H, Wu D, Liu L. Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma. Biosci Rep 2021;41:BSR20202870. [PMID: 33835133 DOI: 10.1042/BSR20202870] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
489 Wu B, Yuan Y, Liu J, Shang H, Dong J, Liang X, Wang D, Chen Y, Wang C, Zhou Y, Jing H, Cheng W. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma. J Nanobiotechnology 2021;19:177. [PMID: 34118951 DOI: 10.1186/s12951-021-00923-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
490 Zhao S, Xu K, Jiang R, Li D, Guo X, Zhou P, Tang J, Li L, Zeng D, Hu L, Ran J, Li J, Chen D. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway. Life Sciences 2020;251:117424. [DOI: 10.1016/j.lfs.2020.117424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
491 Zhang J, Sun N, Guo W, Wu X, Yang X, Jin H, Zhang Y, Wu X, Zhang F, Hu L, Hu H, Gao Y. Identification of NPAC as a novel biomarker and regulator for hepatocellular carcinoma. J Cell Biochem 2019;120:8228-37. [DOI: 10.1002/jcb.28106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
492 Beaufrère A, Caruso S, Calderaro J, Poté N, Bijot JC, Couchy G, Cauchy F, Vilgrain V, Zucman-Rossi J, Paradis V. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol 2021:S0168-8278(21)02099-7. [PMID: 34624411 DOI: 10.1016/j.jhep.2021.09.034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
493 Harmon JS, Kabinejadian F, Seda R, Fabiilli ML, Kuruvilla S, Kuo CC, Greve JM, Fowlkes JB, Bull JL. Minimally invasive gas embolization using acoustic droplet vaporization in a rodent model of hepatocellular carcinoma. Sci Rep 2019;9:11040. [PMID: 31363130 DOI: 10.1038/s41598-019-47309-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
494 Li JJ, Zheng JS, Cui SC, Cui XW, Hu CX, Fang D, Ye LC. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3035-3040 [PMID: 25780303 DOI: 10.3748/wjg.v21.i10.3035] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
495 Ren Z, Yue Y, Zhang Y, Dong J, Liu Y, Yang X, Lin X, Zhao X, Wei Z, Zheng Y, Wang T. Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles. Front Immunol 2021;12:624789. [PMID: 33717135 DOI: 10.3389/fimmu.2021.624789] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
496 Al-Noshokaty TM, Mesbah NM, Abo-Elmatty DM, Abulsoud AI, Abdel-Hamed AR. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis. Life Sci 2022;303:120675. [PMID: 35640776 DOI: 10.1016/j.lfs.2022.120675] [Reference Citation Analysis]
497 Li B, Zhou M, Wang J, Xu H, Yang M. Suppressing ERK Pathway Impairs Glycochenodeoxycholate-Mediated Survival and Drug-Resistance in Hepatocellular Carcinoma Cells. Front Oncol 2021;11:663944. [PMID: 34327135 DOI: 10.3389/fonc.2021.663944] [Reference Citation Analysis]
498 Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, Lleo A. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol 2019; 25(40): 6041-6052 [PMID: 31686761 DOI: 10.3748/wjg.v25.i40.6041] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
499 Chen J, White SB, Harris KR, Li W, Yap JW, Kim DH, Lewandowski RJ, Shea LD, Larson AC. Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. Biomaterials 2015;61:299-306. [PMID: 26022791 DOI: 10.1016/j.biomaterials.2015.05.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
500 Zhou L, Wen J, Huang Z, Nice EC, Huang C, Zhang H, Li Q. Redox proteomics screening cellular factors associated with oxidative stress in hepatocarcinogenesis. Proteomics Clin Appl 2017;11. [PMID: 27763721 DOI: 10.1002/prca.201600089] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
501 Albadawi H, Zhang Z, Altun I, Hu J, Jamal L, Ibsen KN, Tanner EEL, Mitragotri S, Oklu R. Percutaneous liquid ablation agent for tumor treatment and drug delivery. Sci Transl Med 2021;13:eabe3889. [PMID: 33568519 DOI: 10.1126/scitranslmed.abe3889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
502 Liu F, Liu W, Zhou S, Yang C, Tian M, Jia G, Wang H, Zhu B, Feng M, Lu Y, Qiao T, Wang X, Cao W, Wang X, Shi Y, Wu D. Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. J Immunother Cancer 2020;8:e000501. [PMID: 32611686 DOI: 10.1136/jitc-2019-000501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
503 Yang XR, Guo W. ASO Author Reflections: Annexin A3 as a Potential Biomarker for Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:529-30. [PMID: 30519762 DOI: 10.1245/s10434-018-6933-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
504 Deng G, Yao L, Zeng F, Xiao L, Wang Z. Nomogram For Preoperative Prediction Of Microvascular Invasion Risk In Hepatocellular Carcinoma. Cancer Manag Res. 2019;11:9037-9045. [PMID: 31695495 DOI: 10.2147/cmar.s216178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
505 Sun Y, Ma W, Yang Y, He M, Li A, Bai L, Yu B, Yu Z. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian J Pharm Sci 2019;14:581-94. [PMID: 32104485 DOI: 10.1016/j.ajps.2019.04.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 21.7] [Reference Citation Analysis]
506 Li L, Song X, Lv Y, Jiang Q, Fan C, Huang D. Landscape of associations between long non-coding RNAs and infiltrating immune cells in liver hepatocellular carcinoma. J Cell Mol Med 2020;24:11243-53. [PMID: 32910548 DOI: 10.1111/jcmm.15690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
507 Liu X, Ou H, Xiang L, Li X, Huang Y, Yang D. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma. Oncotarget 2017;8:10510-22. [PMID: 28060737 DOI: 10.18632/oncotarget.14446] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
508 Dauch D, Rudalska R, Cossa G, Nault JC, Kang TW, Wuestefeld T, Hohmeyer A, Imbeaud S, Yevsa T, Hoenicke L, Pantsar T, Bozko P, Malek NP, Longerich T, Laufer S, Poso A, Zucman-Rossi J, Eilers M, Zender L. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med 2016;22:744-53. [PMID: 27213815 DOI: 10.1038/nm.4107] [Cited by in Crossref: 129] [Cited by in F6Publishing: 125] [Article Influence: 21.5] [Reference Citation Analysis]
509 Qiu MJ, Zhang L, Chen YB, Zhu LS, Zhang B, Li QT, Yang SL, Xiong ZF. KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma. Int J Biochem Cell Biol 2021;137:106037. [PMID: 34217812 DOI: 10.1016/j.biocel.2021.106037] [Reference Citation Analysis]
510 Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, De Paoli P, Di Francia R. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016;7:428. [PMID: 27881963 DOI: 10.3389/fphar.2016.00428] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
511 Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology. 2016;279:630-640. [PMID: 26744927 DOI: 10.1148/radiol.2015150667] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
512 Wallace D, Cowling TE, Walker K, Suddle A, Gimson A, Rowe I, Callaghan C, Sapisochin G, Mehta N, Heaton N, van der Meulen J. Liver transplantation outcomes after transarterial chemotherapy for hepatocellular carcinoma. British Journal of Surgery 2020;107:1183-91. [DOI: 10.1002/bjs.11559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
513 Sharma RA, Fumi L, Audisio RA, Denys A, Wood BJ, Pignatti F. Commentary: how will interventional oncology navigate the "valleys of death" for new medical devices? Br J Radiol 2018;91:20170643. [PMID: 29172678 DOI: 10.1259/bjr.20170643] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
514 Sun K, Zeng T, Huang D, Liu Z, Huang S, Liu J, Qu Z. MicroRNA-431 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the ZEB1-mediated epithelial-mensenchymal transition. FEBS Open Bio 2015;5:900-7. [PMID: 26697292 DOI: 10.1016/j.fob.2015.11.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
515 Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 2019;70:284-93. [PMID: 30658729 DOI: 10.1016/j.jhep.2018.10.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 32.0] [Reference Citation Analysis]
516 Liao R, Fu YP, Wang T, Deng ZG, Li DW, Fan J, Zhou J, Feng GS, Qiu SJ, Du CY. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. Oncotarget 2017;8:1774-87. [PMID: 27662665 DOI: 10.18632/oncotarget.12152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
517 Zhang HD, Jiang LH, Sun DW, Hou JC, Ji ZL. CircRNA: a novel type of biomarker for cancer. Breast Cancer. 2018;25:1-7. [PMID: 28721656 DOI: 10.1007/s12282-017-0793-9] [Cited by in Crossref: 268] [Cited by in F6Publishing: 296] [Article Influence: 53.6] [Reference Citation Analysis]
518 Ponziani FR, Bhoori S, Germini A, Bongini M, Flores M, Sposito C, Facciorusso A, Gasbarrini A, Mazzaferro V. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. Liver Int 2016;36:1033-42. [PMID: 26709844 DOI: 10.1111/liv.13052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
519 Sacco R, Gadaleta-Caldarola G, Galati G, Lombardi G, Mazza G, Cabibbo G. EASL HCC summit: liver cancer management. Future Oncol. 2014;10:1129-1132. [PMID: 24947253 DOI: 10.2217/fon.14.68] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
520 Wu X, Chen R, Zheng W, Hu H. Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer. Technol Cancer Res Treat 2018;17:1533033818759878. [PMID: 29739274 DOI: 10.1177/1533033818759878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
521 Chen SS, Yu KK, Ling QX, Huang C, Li N, Zheng JM, Bao SX, Cheng Q, Zhu MQ, Chen MQ. The combination of three molecular markers can be a valuable predictive tool for the prognosis of hepatocellular carcinoma patients. Sci Rep. 2016;6:24582. [PMID: 27079415 DOI: 10.1038/srep24582] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
522 Zaki H, Belhassan A, Benlyas M, Lakhlifi T, Bouachrine M. New dehydroabietic acid (DHA) derivatives with anticancer activity against HepG2 cancer cell lines as a potential drug targeting EGFR kinase domain. CoMFA study and virtual ligand-based screening. J Biomol Struct Dyn 2021;39:2993-3003. [PMID: 32319344 DOI: 10.1080/07391102.2020.1759452] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
523 Li L, Xie R, Lu G. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20210760. [PMID: 34027555 DOI: 10.1042/BSR20210760] [Reference Citation Analysis]
524 Pang C, Huang G, Luo K, Dong Y, He F, Du G, Xiao M, Cai W. miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9. Cancer Med 2017;6:2398-409. [PMID: 28940993 DOI: 10.1002/cam4.1188] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
525 Li B, Feng W, Luo O, Xu T, Cao Y, Wu H, Yu D, Ding Y. Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma. Sci Rep 2017;7:5517. [PMID: 28717245 DOI: 10.1038/s41598-017-04811-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
526 Wang K, Li M, Qin J, Sun G, Dai L, Wang P, Ye H, Shi J, Cheng L, Yang Q, Qiu C, Jiang D, Wang X, Zhang J. Serological Biomarkers for Early Detection of Hepatocellular Carcinoma: A Focus on Autoantibodies against Tumor-Associated Antigens Encoded by Cancer Driver Genes. Cancers (Basel) 2020;12:E1271. [PMID: 32443439 DOI: 10.3390/cancers12051271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
527 Xu Q, Yan Y, Gu S, Mao K, Zhang J, Huang P, Zhou Z, Chen Z, Zheng S, Liang J, Lin Z, Wang J, Yan J, Xiao Z. A Novel Inflammation-Based Prognostic Score: The Fibrinogen/Albumin Ratio Predicts Prognoses of Patients after Curative Resection for Hepatocellular Carcinoma. J Immunol Res. 2018;2018:4925498. [PMID: 30027102 DOI: 10.1155/2018/4925498] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
528 Wang J, Luo Z, Yao T, Li W, Pu J. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway. J Cell Physiol 2019;234:6908-16. [PMID: 30317590 DOI: 10.1002/jcp.27449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
529 Deng L, He K, Pan Y, Wang H, Luo Y, Xia Q. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy. Int J Med Sci 2021;18:2109-16. [PMID: 33859517 DOI: 10.7150/ijms.56003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
530 Jia M, Jiang L, Wang YD, Huang JZ, Yu M, Xue HZ. lincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through Notch signaling-induced epithelial-mesenchymal transition. Hepatol Res. 2016;46:1137-1144. [PMID: 27391793 DOI: 10.1111/hepr.12659] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
531 Xiang C, Xiao Y, Ma Z, Peng Y, Li X, Mao X, Li L. Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses. Asia Pac J Clin Oncol 2022. [PMID: 35404506 DOI: 10.1111/ajco.13777] [Reference Citation Analysis]
532 Zhao J, Fu Y, Wu J, Li J, Huang G, Qin L. The Diverse Mechanisms of miRNAs and lncRNAs in the Maintenance of Liver Cancer Stem Cells. Biomed Res Int 2018;2018:8686027. [PMID: 29888282 DOI: 10.1155/2018/8686027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
533 Schwalbe M, Williamson T, Paolucci I, Fuss T, Baumgartner I, Candinas D, Weber S, Tinguely P. A concept for electromagnetic navigated targeting of liver tumors using an angiographic approach. Minim Invasive Ther Allied Technol 2018;27:51-9. [PMID: 29179633 DOI: 10.1080/13645706.2017.1407798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
534 Yang Y, Sun M, Yao W, Wang F, Li X, Wang W, Li J, Gao Z, Qiu L, You R, Yang C, Ba Q, Wang H. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J Immunother Cancer 2020;8:e000317. [PMID: 32179631 DOI: 10.1136/jitc-2019-000317] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
535 Zhong L, Hou C, Zhang L, Zhao J, Li F, Li W. Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. Mol Divers 2019;23:341-50. [DOI: 10.1007/s11030-018-9875-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
536 Yang P, Qiu J, Li J, Wu D, Wan X, Lau WY, Yuan Y, Shen F. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Ann Surg. 2016;263:778-786. [PMID: 26135698 DOI: 10.1097/sla.0000000000001339] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 7.2] [Reference Citation Analysis]
537 Deng L, He K, Pan Y, Wang H, Luo Y, Xia Q. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy. Int J Med Sci 2021;18:2109-16. [PMID: 33859517 DOI: 10.7150/ijms.56003] [Reference Citation Analysis]
538 Yoo S, Kim JY, Lim Y, Han S, Choi J. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus–related hepatocellular carcinoma after surgical resection. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.05.014] [Reference Citation Analysis]
539 Nakagawa H, Fujita M, Fujimoto A. Genome sequencing analysis of liver cancer for precision medicine. Semin Cancer Biol 2019;55:120-7. [PMID: 29605648 DOI: 10.1016/j.semcancer.2018.03.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
540 Wang HY, Zhang B, Zhou JN, Wang DX, Xu YC, Zeng Q, Jia YL, Xi JF, Nan X, He LJ, Yue W, Pei XT. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex. Cell Death Dis 2019;10:453. [PMID: 31186405 DOI: 10.1038/s41419-019-1676-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
541 Sun Y, Lei B, Huang Q. SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR). Med Sci Monit 2019;25:6244-54. [PMID: 31427562 DOI: 10.12659/MSM.915729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
542 Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets. 2015;19:1623-1635. [PMID: 26212068 DOI: 10.1517/14728222.2015.1071354] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
543 Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765-779. [PMID: 25827821 DOI: 10.1586/17474124.2015.1028363] [Cited by in Crossref: 181] [Cited by in F6Publishing: 179] [Article Influence: 25.9] [Reference Citation Analysis]
544 Zhao P, Chen L, Li LH, Wei ZF, Tong B, Jia YG, Kong LY, Xia YF, Dai Y. SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation. BMC Cancer 2014;14:987. [PMID: 25527123 DOI: 10.1186/1471-2407-14-987] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
545 Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]
546 Kim G, Shim JH, Kim M, Kim SY, Won HJ, Shin YM, Kim PN, Kim K, Lee S, Lee HC. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. British Journal of Surgery 2016;103:126-35. [DOI: 10.1002/bjs.9960] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
547 Li TE, Zhang Z, Wang Y, Xu D, Dong J, Zhu Y, Wang Z. A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma. J Cancer 2021;12:2866-76. [PMID: 33854587 DOI: 10.7150/jca.54408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
548 Li X, Liu Z, Wei X, Lin J, Yang Q, Xie Y. Comprehensive Analysis of the Expression and Clinical Significance of THO Complex Members in Hepatocellular Carcinoma. IJGM 2022;Volume 15:2695-713. [DOI: 10.2147/ijgm.s349925] [Reference Citation Analysis]
549 Lin J, Chi MH, Zhang X, Weng SG. Correlation of postoperative splenic volume increase with prognosis of hepatocellular carcinoma after curative hepatectomy. Can J Surg 2019;62:418-25. [PMID: 31782297 DOI: 10.1503/cjs.015918] [Reference Citation Analysis]
550 Umeda S, Kanda M, Sugimoto H, Tanaka H, Hayashi M, Yamada S, Fujii T, Takami H, Niwa Y, Iwata N, Tanaka C, Kobayashi D, Fujiwara M, Kodera Y. Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer 2017;17:610. [PMID: 28863781 DOI: 10.1186/s12885-017-3629-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
551 Wang F, Xie C, Zhao W, Deng Z, Yang H, Fang Q. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Clin Exp Med. 2017;17:33-43. [PMID: 26433964 DOI: 10.1007/s10238-015-0395-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
552 Zhao H, Chen C, Yang C, Mo S, Zhao H, Tian Y. Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153808] [Reference Citation Analysis]
553 Sun R, Zhai R, Ma C, Wei M. WITHDRAWN: The anti-growth and anti-metastasis effects of Schisandrin B on hepatocarcinoma cells in vitro and in vivo. Biochem Biophys Res Commun 2017:S0006-291X(17)31134-8. [PMID: 28601638 DOI: 10.1016/j.bbrc.2017.06.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
554 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Aramaki T, Uesaka K. The Predictors of Microscopic Vessel Invasion Differ Between Primary Hepatocellular Carcinoma and Hepatocellular Carcinoma with a Treatment History. World J Surg 2018;42:3694-704. [PMID: 29872870 DOI: 10.1007/s00268-018-4658-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
555 Colombo M, Bruno S, Lleo A. Hepatitis C virus eradication with direct antiviral agents and liver cancer recurrence: Is the best the enemy of the good? Liver Int 2017;37:1110-2. [DOI: 10.1111/liv.13479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
556 Guan Q, Chen Z, Chen Q, Zhi X. XRCC1 and XPD polymorphisms and their relation to the clinical course in hepatocarcinoma patients. Oncol Lett 2017;14:2783-8. [PMID: 28927037 DOI: 10.3892/ol.2017.6522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
557 Chen Z, Yao L, Liu Y, Zhu P. LncTIC1 interacts with β-catenin to drive liver TIC self-renewal and liver tumorigenesis. Cancer Letters 2018;430:88-96. [DOI: 10.1016/j.canlet.2018.05.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
558 Zhu X, Wu X, Cheng J, Liao H, Di X, Li L, Li R, Zhou Y, Zhang X. Dalbinol, a rotenoid from Amorpha fruticosa L., exerts anti-proliferative activity by facilitating β-catenin degradation in hepatocellular carcinoma cells. Oncotarget 2017;8:47755-66. [PMID: 28548956 DOI: 10.18632/oncotarget.17766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
559 Liu H, Yan Y, Chen R, Zhu M, Lin J, He C, Shi B, Wen K, Mao K, Xiao Z. Integrated nomogram based on five stage-related genes and TNM stage to predict 1-year recurrence in hepatocellular carcinoma. Cancer Cell Int. 2020;20:140. [PMID: 32368186 DOI: 10.1186/s12935-020-01216-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
560 Zhang W, Xie H, Ding S, Xing C, Chen A, Lai M, Zhou L, Zheng S. CADM1 regelates the G1/S transition and represses tumorigenicity through the Rb-E2F pathway in hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2016;15:289-96. [DOI: 10.1016/s1499-3872(16)60099-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
561 Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659 [PMID: 27678348 DOI: 10.3748/wjg.v22.i34.7645] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
562 Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 139] [Article Influence: 22.7] [Reference Citation Analysis]
563 Yu CP, Yu S, Shi L, Wang S, Li ZX, Wang YH, Sun CJ, Liang J. FoxM1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by targeting Snai1. Mol Med Rep 2017;16:5181-8. [PMID: 28849004 DOI: 10.3892/mmr.2017.7223] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
564 Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, Zhou G, Zhou J, Zhang X, Ji W, Yu Z, Li T, Zhu D, Hu W, Ji J, Du H, Shi C, Guo X, Fang J, Han J, Gu W, Xie X, Sun Z, Xu H, Wu X, Hu T, Huang J, Hu H, Zheng J, Luo J, Chen Y, Yu W, Shao G. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. Oncol Res 2020;28:249-71. [PMID: 31856933 DOI: 10.3727/096504019X15766663541105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
565 Min JH, Lee MW, Park HS, Lee DH, Park HJ, Lim S, Choi SY, Lee J, Lee JE, Ha SY, Cha DI, Carriere KC, Ahn JH. Interobserver Variability and Diagnostic Performance of Gadoxetic Acid-enhanced MRI for Predicting Microvascular Invasion in Hepatocellular Carcinoma. Radiology 2020;297:573-81. [PMID: 32990512 DOI: 10.1148/radiol.2020201940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
566 Fabregat I, Caballero-Díaz D. Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis. Front Oncol 2018;8:357. [PMID: 30250825 DOI: 10.3389/fonc.2018.00357] [Cited by in Crossref: 94] [Cited by in F6Publishing: 94] [Article Influence: 23.5] [Reference Citation Analysis]
567 Jeong WK, Jamshidi N, Felker ER, Raman SS, Lu DS. Radiomics and radiogenomics of primary liver cancers. Clin Mol Hepatol 2019;25:21-9. [PMID: 30441889 DOI: 10.3350/cmh.2018.1007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
568 Delicque J, Boulin M, Guiu B, Pelage J, Escal L, Schembri V, Assenat E, Fohlen A. Interventional oncology for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2016;40:530-7. [DOI: 10.1016/j.clinre.2016.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
569 Jin H, Zhang Y, You H, Tao X, Wang C, Jin G, Wang N, Ruan H, Gu D, Huo X, Cong W, Qin W. Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep 2015;5:10466. [PMID: 26099564 DOI: 10.1038/srep10466] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
570 Chen J, Zhou J, Kuang S, Zhang Y, Xie S, He B, Deng Y, Yang H, Shan Q, Wu J, Sirlin CB, Wang J. Liver Imaging Reporting and Data System Category 5: MRI Predictors of Microvascular Invasion and Recurrence After Hepatectomy for Hepatocellular Carcinoma. AJR Am J Roentgenol 2019;213:821-30. [PMID: 31120791 DOI: 10.2214/AJR.19.21168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
571 Désert R, Mebarki S, Desille M, Sicard M, Lavergne E, Renaud S, Bergeat D, Sulpice L, Perret C, Turlin B, Clément B, Musso O. "Fibrous nests" in human hepatocellular carcinoma express a Wnt-induced gene signature associated with poor clinical outcome. Int J Biochem Cell Biol 2016;81:195-207. [PMID: 27545991 DOI: 10.1016/j.biocel.2016.08.017] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
572 Xiao Y, Liu Y, Yang S, Zhang B, Wang T, Jiang D, Zhang J, Yu D, Zhang N. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment. Colloids Surf B Biointerfaces 2016;141:83-92. [PMID: 26844644 DOI: 10.1016/j.colsurfb.2016.01.016] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
573 Ji H, Lu Y, Shi Y. Seeds in the liver. Acta Histochem 2017;119:349-56. [PMID: 28389020 DOI: 10.1016/j.acthis.2017.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
574 Huang Q, Xu E, Tan L, Zeng Q, Zheng R, Li K. Thermal ablation of hepatocellular carcinoma in patients with abnormal coagulation function. Int J Hyperthermia 2018;34:1038-43. [PMID: 29082796 DOI: 10.1080/02656736.2017.1390787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
575 Naseem S, Hussain T, Manzoor S. Interleukin-6: A promising cytokine to support liver regeneration and adaptive immunity in liver pathologies. Cytokine Growth Factor Rev 2018;39:36-45. [PMID: 29361380 DOI: 10.1016/j.cytogfr.2018.01.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
576 Sun J, Zhou G, Xie X, Gu W, Huang J, Zhu D, Hu W, Hou Q, Shi C, Li T, Zhang X, Ji W, Ying S, Peng Z, Zhou J, Yu Z, Ji J, Du H, Guo X, Fang J, Han J, Xu H, Sun Z, Yu W, Shao G, Wu X, Hu H, Li L, Zheng J, Luo J, Chen Y, Cao G, Hu T. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study. Oncol Res 2020;28:75-94. [PMID: 31558180 DOI: 10.3727/096504019X15662966719585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
577 Pan X, Kaminga AC, Wen SW, Liu A. Chemokines in hepatocellular carcinoma: a meta-analysis. Carcinogenesis 2020;41:1682-94. [PMID: 33300549 DOI: 10.1093/carcin/bgaa106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
578 Xue Y, Li T, Liu S, Zhu YY, Wang G, Fu L, Chen L. Effects of Triple Effective RNA (teRNA) on the Inhibition of Hepatocellular Carcinoma Cells. J Cancer 2017;8:3903-15. [PMID: 29151979 DOI: 10.7150/jca.20958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
579 Li F, Bai L, Li S, Chen Y, Xue X, Yu Z. Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. J Cell Biochem 2020. [PMID: 32348599 DOI: 10.1002/jcb.29608] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
580 Yang Y, Fan W, Gu T, Yu L, Chen H, Lv Y, Liu H, Wang G, Zhang D. Radiomic Features of Multi-ROI and Multi-Phase MRI for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma. Front Oncol 2021;11:756216. [PMID: 34692547 DOI: 10.3389/fonc.2021.756216] [Reference Citation Analysis]
581 Olthoff KM, Goldberg DS. The MoRAL Path Beyond Milan. Annals of Surgery 2016;263:851-2. [DOI: 10.1097/sla.0000000000001679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
582 Zhu K, Zhan H, Peng Y, Yang L, Gao Q, Jia H, Dai Z, Tang Z, Fan J, Zhou J. Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Carcinogenesis 2020;41:296-302. [PMID: 31535687 DOI: 10.1093/carcin/bgz154] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 10.5] [Reference Citation Analysis]
583 Kim GH, Kim JH, Shim JH, Ko HK, Chu HH, Shin JH, Yoon HK, Ko GY, Gwon DI. Chemoembolization for Single Large Hepatocellular Carcinoma with Preserved Liver Function: Analysis of Factors Predicting Clinical Outcomes in a 302 Patient Cohort. Life (Basel) 2021;11:840. [PMID: 34440584 DOI: 10.3390/life11080840] [Reference Citation Analysis]
584 Wang D, Liu J, Liu S, Li W. Identification of Crucial Genes Associated With Immune Cell Infiltration in Hepatocellular Carcinoma by Weighted Gene Co-expression Network Analysis. Front Genet 2020;11:342. [PMID: 32391055 DOI: 10.3389/fgene.2020.00342] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
585 Wang Z, Zhu J, Liu Y, Liu C, Wang W, Chen F, Ma L. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. J Transl Med 2020;18:67. [PMID: 32046766 DOI: 10.1186/s12967-020-02255-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 10.5] [Reference Citation Analysis]
586 Li C, Liao J, Wu S, Fan J, Peng Z, Wang Z. Overexpression of DBC1, correlated with poor prognosis, is a potential therapeutic target for hepatocellular carcinoma. Biochem Biophys Res Commun 2017;494:511-7. [PMID: 29106957 DOI: 10.1016/j.bbrc.2017.10.134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
587 Qiao G, Xu H, Li C, Li X, Farooqi AA, Zhao Y, Liu X, Liu M, Stagos D, Lin X. Granulin A Synergizes with Cisplatin to Inhibit the Growth of Human Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E3060. [PMID: 30301274 DOI: 10.3390/ijms19103060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
588 Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. Int J Cancer. 2017;140:390-399. [PMID: 27681592 DOI: 10.1002/ijc.30451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
589 Zheng H, Jiang WH, Tian T, Tan HS, Chen Y, Qiao GL, Han J, Huang SY, Yang Y, Li S, Wang ZG, Gao R, Ren H, Xing H, Ni JS, Wang LH, Ma LJ, Zhou WP. CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma. Oncotarget 2017;8:18872-84. [PMID: 28122351 DOI: 10.18632/oncotarget.14770] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
590 Wu CH, Lan CH, Wu KL, Wu YM, Jane WN, Hsiao M, Wu HC. Hepatocellular carcinoma-targeted nanoparticles for cancer therapy. Int J Oncol 2018;52:389-401. [PMID: 29207071 DOI: 10.3892/ijo.2017.4205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
591 Zhong JH, You XM, Lu SD, Wang YY, Xiang BD, Ma L, Wu FX, Yuan WP, Chen Y, Li LQ. Historical Comparison of Overall Survival after Hepatic Resection for Patients With Large and/or Multinodular Hepatocellular Carcinoma. Medicine (Baltimore). 2015;94:e1426. [PMID: 26334902 DOI: 10.1097/md.0000000000001426] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
592 Fontanellas A, Ávila MA, Berraondo P. Emerging therapies for acute intermittent porphyria. Expert Rev Mol Med 2016;18:e17. [PMID: 27804912 DOI: 10.1017/erm.2016.18] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
593 Xia W, Chen Y, Zhang R, Yan Z, Zhou X, Zhang B, Gao X. Radiogenomics of hepatocellular carcinoma: multiregion analysis-based identification of prognostic imaging biomarkers by integrating gene data-a preliminary study. Phys Med Biol. 2018;63:035044. [PMID: 29311419 DOI: 10.1088/1361-6560/aaa609] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
594 Zhang W, Tan Y, Jiang L, Yan L, Li B, Wen T, Yang J. Liver resection associated with better outcomes for single large hepatocellular carcinoma located in the same section. Medicine (Baltimore) 2017;96:e6246. [PMID: 28272222 DOI: 10.1097/MD.0000000000006246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
595 Yuan BH, Yuan WP, Li RH, Xiang BD, Gong WF, Li LQ, Zhong JH. Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. Tumour Biol. 2016;37:2435-2441. [PMID: 26383523 DOI: 10.1007/s13277-015-4091-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
596 Li WC, Xiong ZY, Huang PZ, Liao YJ, Li QX, Yao ZC, Liao YD, Xu SL, Zhou H, Wang QL, Huang H, Zhang P, Lin JZ, Liu B, Ren J, Hu KP. KCNK levels are prognostic and diagnostic markers for hepatocellular carcinoma. Aging (Albany NY) 2019;11:8169-82. [PMID: 31581133 DOI: 10.18632/aging.102311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
597 Liu W, Liu Y, Liu H, Zhang W, Fu Q, Xu J, Gu J. Tumor Suppressive Function of p21-activated Kinase 6 in Hepatocellular Carcinoma. J Biol Chem 2015;290:28489-501. [PMID: 26442588 DOI: 10.1074/jbc.M115.658237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
598 Chen C, An L, Cheng Y, Luo X, Li Z, Liu X. Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. Front Oncol 2020;10:1404. [PMID: 32983970 DOI: 10.3389/fonc.2020.01404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
599 Wang D, Du X, Bai T, Chen M, Chen J, Liu J, Li L, Li H, Zhang C. Decreased Expression of Long Non-Coding RNA GMDS Divergent Transcript (GMDS-DT) is a Potential Biomarker for Poor Prognosis of Hepatocellular Carcinoma. Med Sci Monit 2019;25:6221-9. [PMID: 31423008 DOI: 10.12659/MSM.917663] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
600 Huang R, Huang X, Zhang B, Jia H, Liao Z, Wang H. 16-O-caffeoyl-16-hydroxylhexadecanoic acid, a medicinal plant-derived phenylpropanoid, induces apoptosis in human hepatocarcinoma cells through ROS-dependent endoplasmic reticulum stress. Phytomedicine 2018;41:33-44. [DOI: 10.1016/j.phymed.2018.01.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
601 Yang C, Wang S, Ruan H, Li B, Cheng Z, He J, Zuo Q, Yu C, Wang H, Lv Y, Gu D, Jin G, Yao M, Qin W, Jin H. Downregulation of PDK4 Increases Lipogenesis and Associates with Poor Prognosis in Hepatocellular Carcinoma. J Cancer 2019;10:918-26. [PMID: 30854098 DOI: 10.7150/jca.27226] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
602 Chen QL, Yan Q, Feng KL, Xie CF, Fang CK, Wang JN, Liu LH, Li Y, Zhong C. Using Integrated Bioinformatics Analysis to Identify Abnormally Methylated Differentially Expressed Genes in Hepatocellular Carcinoma. Int J Gen Med 2021;14:805-23. [PMID: 33732011 DOI: 10.2147/IJGM.S294505] [Reference Citation Analysis]
603 Liu D, Kang H, Gao M, Jin L, Zhang F, Chen D, Li M, Xiao L. Exosome-transmitted circ_MMP2 promotes hepatocellular carcinoma metastasis by upregulating MMP2. Mol Oncol 2020;14:1365-80. [PMID: 31944556 DOI: 10.1002/1878-0261.12637] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
604 Reig M, Bruix J. Pattern of tumor progression in liver cancer: The missing partner in trial design. Hepatology 2015;62:674-6. [PMID: 25953295 DOI: 10.1002/hep.27881] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
605 Zheng W, Yao M, Wu M, Yang J, Yao D, Wang L. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis. J Transl Med 2020;18:81. [PMID: 32059741 DOI: 10.1186/s12967-020-02262-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
606 Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology 2016;63:1707-17. [PMID: 26703761 DOI: 10.1002/hep.28420] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 13.2] [Reference Citation Analysis]
607 Zheng J, Zhang C, Li Y, Jiang Y, Xing B, Du X. p21-activated kinase 6 controls mitosis and hepatocellular carcinoma progression by regulating Eg5. Biochim Biophys Acta Mol Cell Res 2021;1868:118888. [PMID: 33098954 DOI: 10.1016/j.bbamcr.2020.118888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
608 Liu P, Hsu C, Hsia C, Lee Y, Huang Y, Su C, Lee F, Lin H, Huo T. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. European Journal of Cancer 2016;63:25-33. [DOI: 10.1016/j.ejca.2016.04.023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
609 Sangiovanni A, Colombo M. A therapeutic conundrum: Delaying ablation of small nonresectable early hepatocellular carcinoma to facilitate liver transplantation. Liver Transpl 2016;22:161-2. [PMID: 26663560 DOI: 10.1002/lt.24382] [Reference Citation Analysis]
610 Wang X, Wang Q. Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity.Can J Gastroenterol Hepatol. 2018;2018:9049252. [PMID: 29805966 DOI: 10.1155/2018/9049252] [Cited by in Crossref: 21] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
611 Zhong J, Yu X, Dong X, Lu H, Zhou W, Li L, Li Z, Sun P, Shi X. Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells. Oncol Lett 2018;15:7191-9. [PMID: 29731881 DOI: 10.3892/ol.2018.8186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
612 Wei Y, Lv B, Xie J, Zhang Y, Lin Y, Wang S, Zhong J, Chen Y, Peng Y, Ma J. Plumbagin promotes human hepatoma SMMC-7721 cell apoptosis via caspase-3/vimentin signal-mediated EMT. Drug Des Devel Ther 2019;13:2343-55. [PMID: 31409969 DOI: 10.2147/DDDT.S204787] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
613 Zhang X, Du L, Qiao Y, Zhang X, Zheng W, Wu Q, Chen Y, Zhu G, Liu Y, Bian Z, Guo S, Yang Y, Ma L, Yu Y, Pan Q, Sun F, Wang J. Ferroptosis is governed by differential regulation of transcription in liver cancer. Redox Biol 2019;24:101211. [PMID: 31108460 DOI: 10.1016/j.redox.2019.101211] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
614 Xu JX, Xing WT, Peng YC, Chen YY, Qi LN. Outcomes of postoperative adjuvant transarterial chemoembolization for hepatocellular carcinoma according to the Ki67 index. Future Oncol 2022. [PMID: 35266821 DOI: 10.2217/fon-2021-1443] [Reference Citation Analysis]
615 Zhu X, Qin M, Li C, Zeng W, Bei C, Tan C, Zhang Y, Shi W, Kong J, Fu Y, Tan S. Downregulated Expression of Chromobox Homolog 7 in Hepatocellular Carcinoma. Genet Test Mol Biomarkers 2019;23:348-52. [PMID: 30990338 DOI: 10.1089/gtmb.2018.0293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
616 Lorenzin D, Pravisani R, Leo CA, Bugiantella W, Soardo G, Carnelutti A, Umberto B, Risaliti A. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. Cancer Biotherapy and Radiopharmaceuticals 2016;31:65-9. [DOI: 10.1089/cbr.2015.1905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
617 Chen ZB, Qin F, Ye Z, Shen SQ, Li W, Ding YM, Hu QY, Ma Y. Microwave-assisted liver resection vs. clamp crushing liver resection in cirrhosis patients with hepatocellular carcinoma. Int J Hyperthermia 2018;34:1359-66. [PMID: 29353503 DOI: 10.1080/02656736.2018.1429678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
618 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
619 Takaki S, Fukuhara T, Mori N, Tsuji K. High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma. Mol Clin Oncol 2020;12:60-8. [PMID: 31814977 DOI: 10.3892/mco.2019.1949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
620 Bettinger D, Gkika E, Schultheiss M, Glaser N, Lange S, Maruschke L, Buettner N, Kirste S, Nestle U, Grosu AL, Thimme R, Brunner TB. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. BMC Cancer 2018;18:807. [PMID: 30092781 DOI: 10.1186/s12885-018-4696-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
621 Zhang J, Xue F, Chen S, Zhang D, Lu C, Tang G. The influence of caveolin-1 gene polymorphisms on hepatitis B virus-related hepatocellular carcinoma susceptibility in Chinese Han population: A case-control study. Medicine (Baltimore) 2017;96:e7359. [PMID: 29049173 DOI: 10.1097/MD.0000000000007359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
622 Benbow JH, Thompson KJ, Cope HL, Brandon-Warner E, Culberson CR, Bossi KL, Li T, Russo MW, Gersin KS, McKillop IH, deLemos AS, Schrum LW. Diet-Induced Obesity Enhances Progression of Hepatocellular Carcinoma through Tenascin-C/Toll-Like Receptor 4 Signaling. Am J Pathol. 2016;186:145-158. [PMID: 26603137 DOI: 10.1016/j.ajpath.2015.09.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
623 Ardelt MA, Fröhlich T, Martini E, Müller M, Kanitz V, Atzberger C, Cantonati P, Meßner M, Posselt L, Lehr T, Wojtyniak JG, Ulrich M, Arnold GJ, König L, Parazzoli D, Zahler S, Rothenfußer S, Mayr D, Gerbes A, Scita G, Vollmar AM, Pachmayr J. Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy. Hepatology 2019;69:376-93. [PMID: 30033593 DOI: 10.1002/hep.30190] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
624 Lin ZX, Ruan DY, Jia CC, Wang TT, Cheng JT, Huang HQ, Wu XY. Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy. Clin Transl Oncol 2020;22:370-80. [PMID: 31201606 DOI: 10.1007/s12094-019-02137-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
625 Liu M, Zhong YB, Shao J, Zhang C, Shi C. Tumor-associated macrophages promote human hepatoma Huh-7 cell migration and invasion through the Gli2/IGF-II/ERK1/2 axis by secreting TGF-β1. Cancer Biol Ther 2020;21:1041-50. [PMID: 33081566 DOI: 10.1080/15384047.2020.1824478] [Reference Citation Analysis]
626 Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C. Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin. J Exp Clin Cancer Res 2016;35:126. [PMID: 27514687 DOI: 10.1186/s13046-016-0402-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
627 Wang Z, Shao D, Chang Z, Lu M, Wang Y, Yue J, Yang D, Li M, Xu Q, Dong WF. Janus Gold Nanoplatform for Synergetic Chemoradiotherapy and Computed Tomography Imaging of Hepatocellular Carcinoma. ACS Nano 2017;11:12732-41. [PMID: 29140684 DOI: 10.1021/acsnano.7b07486] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 21.0] [Reference Citation Analysis]
628 Shim JJ, Kim GA, Oh CH, Kim JW, Myung J, Kim BH, Oh IH. Reduced liver cancer mortality with regular clinic follow-up among patients with chronic hepatitis B: A nationwide cohort study. Cancer Med 2020;9:7781-91. [PMID: 32857923 DOI: 10.1002/cam4.3421] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
629 Satiya J, Schwartz I, Tabibian JH, Kumar V, Girotra M. Ablative therapies for hepatic and biliary tumors: endohepatology coming of age. Transl Gastroenterol Hepatol 2020;5:15. [PMID: 32258519 DOI: 10.21037/tgh.2019.10.17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
630 Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol 2015; 7(26): 2648-2663 [PMID: 26609342 DOI: 10.4254/wjh.v7.i26.2648] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 16.6] [Reference Citation Analysis]
631 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10584-10597 [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
632 Zhang N, Wang LR, Li DD, Ma DN, Wang CH, He XG, Gao DM, Wang L, Tang ZY. Interferon-α Combined With Herbal Compound "Songyou Yin" Effectively Inhibits the Increased Invasiveness and Metastasis by Insufficient Radiofrequency Ablation of Hepatocellular Carcinoma in an Animal Model. Integr Cancer Ther 2018;17:1260-9. [PMID: 30234394 DOI: 10.1177/1534735418801525] [Reference Citation Analysis]
633 Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, Morisco F, Vitale A, Russo FP, Cillo U, Burra P, Mescoli C, Gambato M, Sessa A, Cabibbo G, Viganò M, Galati G, Villa E, Iavarone M, Brancaccio G, Rendina M, Lupo LG, Losito F, Fucilli F, Persico M, D’ambrosio R, Sangiovanni A, Cucchetti A, Trevisani e Matteo Renzulli F, Miele L, Grieco A, Lodovico Rapaccini G, Pompili M, Gasbarrini A, Battista Levi Sandri G, Melandro F, Rossi M, Lenci I, Manzia TM, Tortora R, Di Costanzo GG, Sacco R, Ghinolfi D, Rreka E, Carrai P, Simonetti N, Sposito C, Bhoori S, di Sandro S, Foschi FG, Casadei Gardini A, Nicolini D, Mazzocato S, Kostandini A, Violi P, Baccarani U, Pravisani R, Vincenzi V. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Digestive and Liver Disease 2018;50:1105-14. [DOI: 10.1016/j.dld.2018.08.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
634 Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Katano Y, Hirooka Y, Ishikawa T, Nakano I, Goto H. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. PLoS One. 2015;10:e0138776. [PMID: 26421430 DOI: 10.1371/journal.pone.0138776] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
635 Muzica CM, Stanciu C, Huiban L, Singeap AM, Sfarti C, Zenovia S, Cojocariu C, Trifan A. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol 2020; 26(43): 6770-6781 [PMID: 33268960 DOI: 10.3748/wjg.v26.i43.6770] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
636 . Retraction. American Journal of Physiology-Gastrointestinal and Liver Physiology 2020;319:G636-G636. [DOI: 10.1152/ajpgi.00161.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
637 Liu S, Li X, Li H, Guo L, Zhang B, Zhang J, Ye Q. Is the Hong Kong Liver Cancer staging system the best guide for hepatitis B virus-related hepatocellular carcinoma patients with multiple tumors? Oncotarget 2016;7:51598-607. [PMID: 27323396 DOI: 10.18632/oncotarget.9956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
638 Zhang H, Zhang Y, Zhu X, Chen C, Zhang C, Xia Y, Zhao Y, Andrisani O, Kong L. DEAD Box Protein 5 Inhibits Liver Tumorigenesis by Stimulating Autophagy via Interaction with p62/SQSTM1. Hepatology 2019;69:1046-63. [PMID: 30281815 DOI: 10.1002/hep.30300] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
639 Thin KZ, Liu X, Feng X, Raveendran S, Tu JC. LncRNA-DANCR: A valuable cancer related long non-coding RNA for human cancers. Pathol Res Pract 2018;214:801-5. [PMID: 29728310 DOI: 10.1016/j.prp.2018.04.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
640 Nomura A, Terashima T, Mizukoshi E, Kitahara M, Murayama T, Kaneko S. Protocol For An Adjuvant Alpha-Fetoprotein-Derived Peptide After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: Safety Study. JMIR Res Protoc 2020;9:e17082. [PMID: 32039814 DOI: 10.2196/17082] [Reference Citation Analysis]
641 Liu LF, Ding ZL, Zhong JH, Li HX, Liu JJ, Li H, Li LQ. Contrast-Enhanced Ultrasound to Monitor Early Recurrence of Primary Hepatocellular Carcinoma after Curative Treatment. Biomed Res Int 2018;2018:8910562. [PMID: 30533441 DOI: 10.1155/2018/8910562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
642 Sun FK, Sun Q, Fan YC, Gao S, Zhao J, Li F, Jia YB, Liu C, Wang LY, Li XY, Ji XF, Wang K. Methylation of tissue factor pathway inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma after hepatectomy. J Gastroenterol Hepatol 2016;31:484-92. [PMID: 26313014 DOI: 10.1111/jgh.13154] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
643 Athanasopoulos PG, Hadjittofi C, Luong TV, O'Beirne J, Sharma D. Synchronous Hepatic Epithelioid Hemangioendothelioma and Hepatocellular Carcinoma: First Case Report in the Literature and Challenges. Medicine (Baltimore) 2015;94:e1377. [PMID: 26313777 DOI: 10.1097/MD.0000000000001377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
644 Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma – A novel therapeutic approach. Journal of Hepatology 2015;63:102-13. [DOI: 10.1016/j.jhep.2015.01.031] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
645 Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 2018;48:814-20. [PMID: 29682855 DOI: 10.1111/hepr.13180] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
646 Zheng Y, Wang K, Zhou J, Zhang Z, Xiong L, Wen Y, Zou H. Portal hypertension predicts short-term and long-term outcomes after hepatectomy in hepatocellular carcinoma patients. Scandinavian Journal of Gastroenterology 2018;53:1562-8. [DOI: 10.1080/00365521.2018.1538386] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
647 Mazza G, Telese A, Al-Akkad W, Frenguelli L, Levi A, Marrali M, Longato L, Thanapirom K, Vilia MG, Lombardi B, Crowley C, Crawford M, Karsdal MA, Leeming DJ, Marrone G, Bottcher K, Robinson B, Del Rio Hernandez A, Tamburrino D, Spoletini G, Malago M, Hall AR, Godovac-Zimmermann J, Luong TV, De Coppi P, Pinzani M, Rombouts K. Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition. Cells 2019;9:E83. [PMID: 31905709 DOI: 10.3390/cells9010083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
648 Chu H, Wu C, Zhao Q, Sun R, Yang K, Zhao B, Liu Y, Liang Z, Zhong S, Zhang L, Zhang Y. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells. Carcinogenesis 2021;42:753-61. [PMID: 33677528 DOI: 10.1093/carcin/bgab019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
649 Yang Z, Duan J, Wang J, Liu Q, Shang R, Yang X, Lu P, Xia C, Wang L, Dou K. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy. Int J Nanomedicine 2018;13:1851-65. [PMID: 29618926 DOI: 10.2147/IJN.S155537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
650 Perkons NR, Johnson O, Pilla G, Profka E, Mercadante M, Ackerman D, Gade TPF. Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer. Clin Cancer Res 2020;26:4581-9. [PMID: 32499234 DOI: 10.1158/1078-0432.CCR-20-0826] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
651 Qin C, Gao Y, Li J, Huang C, He S. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett 2021;21:487. [PMID: 33968203 DOI: 10.3892/ol.2021.12748] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
652 Hu H, Wang Z, Huang X, Chen S, Zheng X, Ruan S, Xie X, Lu M, Yu J, Tian J, Liang P, Wang W, Kuang M. Ultrasound-based radiomics score: a potential biomarker for the prediction of microvascular invasion in hepatocellular carcinoma. Eur Radiol 2019;29:2890-901. [DOI: 10.1007/s00330-018-5797-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 11.8] [Reference Citation Analysis]
653 Zhu B, Wang J, Li H, Chen X, Zeng Y. Living or deceased organ donors in liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. HPB 2019;21:133-47. [DOI: 10.1016/j.hpb.2018.11.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
654 Liu F, Wu X, Jiang X, Qian Y, Gao J. Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3β/β-catenin signalling. J Exp Clin Cancer Res 2018;37:122. [PMID: 29940988 DOI: 10.1186/s13046-018-0801-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
655 Uchikawa S, Kawaoka T, Namba M, Kodama K, Ohya K, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Chayama K, Aikata H. Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. Liver Cancer 2020;9:148-55. [PMID: 32399429 DOI: 10.1159/000503829] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
656 Chen H, Kong M, Chen Y, Jiang Y, Wen M, Zhang X. Prognostic significance of miR-203 and ZEB1 expression in early-stage hepatocellular carcinoma. J Cancer 2021;12:4810-8. [PMID: 34234851 DOI: 10.7150/jca.57819] [Reference Citation Analysis]
657 Zhou HH, Chen L, Liang HF, Li GZ, Zhang BX, Chen XP. Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT. Int J Mol Sci 2016;17:E610. [PMID: 27110775 DOI: 10.3390/ijms17040610] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
658 Fan W, Xu Y, Li Z, Li Q. Folic acid-modified β-cyclodextrin nanoparticles as drug delivery to load DOX for liver cancer therapeutics. Soft Materials 2019;17:437-47. [DOI: 10.1080/1539445x.2019.1624265] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
659 Wang MD, Li C, Li J, Zhang WG, Jiang WQ, Yu JJ, Xing H, Wu H, Han J, Li ZL, Xu XF, Chen TH, Zhou YH, Gu WM, Wang H, Zeng YY, Zhang YM, Pawlik TM, Lau WY, Wu MC, Yang JM, Shen F, Yang T. Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort Study. Oncologist 2019;24:e730-9. [PMID: 31127021 DOI: 10.1634/theoncologist.2018-0898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
660 Shao Z, Ji W, Liu A, Qin A, Shen L, Li G, Zhou Y, Hu X, Yu E, Jin G. TSG101 Silencing Suppresses Hepatocellular Carcinoma Cell Growth by Inducing Cell Cycle Arrest and Autophagic Cell Death. Med Sci Monit 2015;21:3371-9. [PMID: 26537625 DOI: 10.12659/msm.894447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
661 Dong W, Yu H, Zhu YY, Xian ZH, Chen J, Wang H, Shi CC, Jin GZ, Dong H, Cong WM. A Novel Pathological Scoring System for Hepatic Cirrhosis with Hepatocellular Carcinoma. Cancer Manag Res 2020;12:5537-47. [PMID: 32753967 DOI: 10.2147/CMAR.S223417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
662 Chen Z, Gao Y, Yao L, Liu Y, Huang L, Yan Z, Zhao W, Zhu P, Weng H. LncFZD6 initiates Wnt/β-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation. Oncogene 2018;37:3098-112. [PMID: 29535420 DOI: 10.1038/s41388-018-0203-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
663 Jiang T, Huang Z, Zhang S, Zou W, Xiang L, Wu X, Shen Y, Liu W, Zeng Z, Zhao A, Zhou S, Zeng Q. miR‑23b inhibits proliferation of SMMC‑7721 cells by directly targeting IL‑11. Mol Med Rep 2018;18:1591-9. [PMID: 29901200 DOI: 10.3892/mmr.2018.9151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
664 Takeda H, Takai A, Inuzuka T, Marusawa H. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: Linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26-38. [PMID: 27714455 DOI: 10.1007/s00535-016-1273-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
665 Bu Y, Liu F, Jia QA, Yu SN. Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0165681. [PMID: 27814372 DOI: 10.1371/journal.pone.0165681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
666 Liu H, Wang Y, Chen B, Shen X, Li W. Effects of Lidocaine-Mediated CPEB3 Upregulation in Human Hepatocellular Carcinoma Cell Proliferation In Vitro. Biomed Res Int 2018;2018:8403157. [PMID: 29850575 DOI: 10.1155/2018/8403157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
667 Feng J, Chen J, Zhu R, Yu L, Zhang Y, Feng D, Kong H, Song C, Xia H, Wu J, Zhao D. Prediction of early recurrence of hepatocellular carcinoma within the Milan criteria after radical resection. Oncotarget 2017;8:63299-310. [PMID: 28968990 DOI: 10.18632/oncotarget.18799] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
668 Liu F, Li C, Zhu J, Ren L, Qi X. ABO blood type and risk of hepatocellular carcinoma: a meta-analysis. Expert Rev Gastroenterol Hepatol 2018;12:927-33. [PMID: 30004289 DOI: 10.1080/17474124.2018.1500174] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
669 Zhang JY, Xu D, Liu ZZ, Li Y, Wang LJ, Xing BC. Human U Three Protein 14a Expression is Increased in Hepatocellular Carcinoma and Associated with Poor Prognosis. Chin Med J (Engl) 2017;130:470-6. [PMID: 28218222 DOI: 10.4103/0366-6999.199839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
670 Li T, Chen X, Liu Y, Fan L, Lin L, Xu Y, Chen S, Shao J. pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer. European Journal of Pharmaceutical Sciences 2017;96:456-63. [DOI: 10.1016/j.ejps.2016.10.019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
671 Lu X, Ge G, Ji F, Wang J. LncRNA MORT Overexpression Inhibits Cancer Cell Migration and Invasion in Hepatocellular Carcinoma by Downregulating NOTCH1. Cancer Biother Radiopharm 2021. [PMID: 33493420 DOI: 10.1089/cbr.2020.4020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
672 Xiao F, Li H, Feng Z, Huang L, Kong L, Li M, Wang D, Liu F, Zhu Z, Wei Y, Zhang W. Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade. Sci Rep 2021;11:488. [PMID: 33436794 DOI: 10.1038/s41598-020-80066-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
673 Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Reference Citation Analysis]
674 Jin B, Gong Z, Yang N, Huang Z, Zeng S, Chen H, Hu S, Pan G. Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis. Tumour Biol 2016;37:5911-7. [PMID: 26592251 DOI: 10.1007/s13277-015-4443-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
675 Lin J, Zhang F. Identification of Three Key Genes Associated with Hepatocellular Carcinoma Progression Based on Co-expression Analysis. Cell Biochem Biophys 2021. [PMID: 34406599 DOI: 10.1007/s12013-021-01028-2] [Reference Citation Analysis]
676 Ezaka K, Kanda M, Sugimoto H, Shimizu D, Oya H, Nomoto S, Sueoka S, Tanaka Y, Takami H, Hashimoto R. Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Ann Surg Oncol. 2015;22 Suppl 3:S1499-S1507. [PMID: 26122373 DOI: 10.1245/s10434-015-4695-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
677 Wang W, Xu C, Wang H, Jiang C. Identification of nanobodies against hepatocellular carcinoma marker glypican-3. Mol Immunol 2021;131:13-22. [PMID: 33453658 DOI: 10.1016/j.molimm.2021.01.010] [Reference Citation Analysis]
678 Enooku K, Uranbileg B, Ikeda H, Kurano M, Sato M, Kudo H, Maki H, Koike K, Hasegawa K, Kokudo N, Yatomi Y. Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels. PLoS One 2016;11:e0161825. [PMID: 27583415 DOI: 10.1371/journal.pone.0161825] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
679 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016; 8(1): 58-68 [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
680 Shi G, Wang C, Zhang P, Ji L, Xu S, Tan X, Li H. Donor Polymorphisms of Toll-like Receptor 4 rs1927914 Associated with the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation. Arch Med Res 2017;48:553-60. [PMID: 29221801 DOI: 10.1016/j.arcmed.2017.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
681 Li W, Liao X, Ning P, Cao Y, Zhang M, Bu Y, Lv J, Jia Q. Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma. BMC Cancer 2019;19:395. [PMID: 31029128 DOI: 10.1186/s12885-019-5603-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
682 Chen W, Yang J, Zhang Y, Cai H, Chen X, Sun D. Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. FEBS Open Bio 2019;9:335-47. [PMID: 30761258 DOI: 10.1002/2211-5463.12578] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
683 Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. J Cancer. 2016;7:1907-1914. [PMID: 27698932 DOI: 10.7150/jca.15823] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
684 Nahon P, Nault J. Constitutional and functional genetics of human alcohol-related hepatocellular carcinoma. Liver Int 2017;37:1591-601. [DOI: 10.1111/liv.13419] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
685 Wallace D, Cowling TE, Suddle A, Gimson A, Rowe I, Callaghan C, Sapisochin G, Ivanics T, Claasen M, Mehta N, Heaton N, van der Meulen J, Walker K. National time trends in mortality and graft survival following liver transplantation from circulatory death or brainstem death donors. Br J Surg 2021:znab347. [PMID: 34738095 DOI: 10.1093/bjs/znab347] [Reference Citation Analysis]
686 Kolly P, Dufour JF. Hepatocellular carcinoma: asphyxiate and then cook. Hepat Oncol 2016;3:1-3. [PMID: 30191021 DOI: 10.2217/hep.15.31] [Reference Citation Analysis]
687 Shao D, Li J, Pan Y, Zhang X, Zheng X, Wang Z, Zhang M, Zhang H, Chen L. Noninvasive theranostic imaging of HSV-TK/GCV suicide gene therapy in liver cancer by folate-targeted quantum dot-based liposomes. Biomater Sci 2015;3:833-41. [DOI: 10.1039/c5bm00077g] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 5.6] [Reference Citation Analysis]
688 Liu J, Chen L, Pan J, Chen M, Zhou J, Zhou F, Chen P, Song Y. Comprehensive analysis of key lncRNAs in HCV-positive hepatocellular carcinoma. Arch Med Sci 2021;17:142-51. [PMID: 33488867 DOI: 10.5114/aoms.2020.100675] [Reference Citation Analysis]
689 Wallace D, Cowling TE, Walker K, Suddle A, Rowe I, Callaghan C, Gimson A, Bernal W, Heaton N, van der Meulen J. Short- and long-term mortality after liver transplantation in patients with and without hepatocellular carcinoma in the UK. British Journal of Surgery 2020;107:896-905. [DOI: 10.1002/bjs.11451] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
690 Wu L, Pang Y, Qin G, Xi G, Wu S, Wang X, Chen T. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives. PLoS One 2017;12:e0171840. [PMID: 28182780 DOI: 10.1371/journal.pone.0171840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
691 Yan X, Fu X, Cai C, Zi X, Yao H, Qiu Y. Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort. European Journal of Gastroenterology & Hepatology 2015;27:1180-6. [DOI: 10.1097/meg.0000000000000418] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
692 Martins AMA, Garcia JHP, Eberlin MN. Mass Spectrometry as a Clinical Integrative Tool to Evaluate Hepatocellular Carcinoma: Moving to the Mainstream. Expert Rev Gastroenterol Hepatol 2019;13:821-5. [PMID: 31382786 DOI: 10.1080/17474124.2019.1651643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
693 Song L, Luo Y, Wang X, Almutairi MM, Pan H, Li W, Liu Y, Wang Q, Hong M. Exploring the active mechanism of berberine against HCC by systematic pharmacology and experimental validation. Mol Med Rep 2019;20:4654-64. [PMID: 31545468 DOI: 10.3892/mmr.2019.10698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
694 Chen Y, Chan S, Lin P, Chu P. The expression of a tumor suppressor gene JDP2 and its prognostic value in hepatocellular carcinoma patients. Human Pathology 2017;63:212-6. [DOI: 10.1016/j.humpath.2017.03.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
695